Original Article
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
N Engl J Med 1994; 330:1260-1266May 5, 1994
- Abstract
Background
The role of molecular markers in predicting the response to treatment of breast cancer is poorly defined. The Cancer and Leukemia Group B (CALGB) conducted a randomized adjuvant-chemotherapy trial (CALGB 8541) comparing three doses (high, moderate, and low) of cyclophosphamide, doxorubicin, and fluorouracil in 1572 women with node-positive breast cancer. This study (CALGB 8869) was designed to determine whether the DNA index, the S-phase fraction, c-erbB-2 expression, or p53 accumulation could be used as a marker to identify a subgroup of patients more likely than others to benefit from high doses of chemotherapy.
Methods
Tissue blocks were obtained from 442 patients randomly selected from the larger CALGB trial. Paraffin sections from the primary lesions were analyzed for DNA content, S-phase fraction, c-erbB-2 expression, and p53 accumulation.
Results
Patients randomly assigned to the high-dose regimen of adjuvant chemotherapy had significantly longer disease-free and overall survival if their tumors had c-erbB-2 overexpression. No further information was gained by adding the data on S-phase fraction or p53 accumulation to the analysis. There was no clear evidence of a dose-response effect in patients with minimal or no c-erbB-2 expression.
Conclusions
There is a significant dose-response effect of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil in patients with overexpression of c-erbB-2 but not in patients with no c-erbB-2 expression or minimal c-erbB-2 expression. Overexpression of c-erbB-2 may be a useful marker to identify the patients who are most likely to benefit from high doses of adjuvant chemotherapy.
Media in This Article
Figure 1
Disease-free and Overall Survival According to Treatment Group (High-Dose, Moderate-Dose, or Low-Dose Chemotherapy) and Level of c-erbB-2 Expression.Table 1
Characteristics of Patients with Node-Positive Early Breast Cancer.Article Activity
- Article
Several molecular markers have been associated with a poor prognosis in patients with breast cancer, and it is widely assumed that the presence of these markers is an indication for adjuvant therapy. Many physicians and patients believe that it is better to try chemotherapy in such cases, even if it may be ineffective, than to do nothing and let the patient die. However, it is likely that some prognostic factors can be used to identify a tumor that is intrinsically resistant to moderate doses of chemotherapy, in which case such therapy is likely to compromise substantially the patient's quality of life without prolonging it. This issue is particularly important with such treatments as high-dose chemotherapy and autologous bone marrow transplantation, since the associated toxic effects and financial costs are substantial.
Prognostic factors that may help predict a recurrence of breast cancer include the size of the tumor,1 number of lymph nodes involved,1,2 histologic grade,3 and estrogen and progesterone status4. New molecular prognostic factors may also aid in the selection of a treatment5. Measurements of tumor DNA content (ploidy), cell proliferation (S-phase fraction), and oncogene expression have been reported to help predict relapse and survival, especially in patients with node-negative breast cancer. Flow cytometry is a rapid means of assessing cellular DNA content and cell proliferation6 and can be performed with paraffin-embedded tumor sections, thus facilitating a retrospective analysis7,8. The c-erbB-2 (HER-2/neu) oncogene is a potentially useful prognostic marker that encodes a transmembrane glycoprotein whose extracellular region is structurally similar to that of the epidermal-growth-factor receptor9-11. Like the epidermal growth factor, c-erbB-2 expression reflects an increase in the proliferative activity of a tumor12,13. Overexpression of c-erbB-2 has been demonstrated in 15 to 30 percent of patients with breast cancer and has been found by most but not all investigators to be associated with shorter survival, particularly in patients with positive nodes14-18. Another molecular marker is the tumor suppressor gene p5319-22. Mutations of this gene, which have been found in 13 to 49 percent of patients with breast carcinomas,23 may have prognostic importance, particularly in patients with node-negative disease24-26.
Patients with tumors that are positive for estrogen receptors derive the greatest benefit from adjuvant endocrine therapy10,27. However, the relation between prognostic factors and the response to adjuvant chemotherapy is less clear28-31. In patients with tumors of unfavorable grade28,29 or a high thymidine-labeling index,30,31 adjuvant chemotherapy has improved disease-free and overall survival, but the value of flow cytometry and c-erbB-2 and p53 studies to predict therapeutic responses in patients with node-positive breast cancer is uncertain. Since the DNA content, S-phase fraction, and c-erbB-2 and p53 expression are indirect measures of proliferative activity, we hypothesized that they might help predict the outcome of treatment. We tested our hypothesis with biopsy material from a randomized trial, reported elsewhere in this issue,32 comparing three doses of adjuvant chemotherapy to determine whether dose and dose intensity were related to survival in women with node-positive, stage II breast cancer.
Methods
Subjects
The patients in this study (CALGB 8869) were drawn from the larger trial of adjuvant chemotherapy (CALGB 8541). They were randomly selected from the 12 strata defined by the year of enrollment in the study (1985, 1986, 1987, or 1988) and the treatment received (a low-, moderate-, or high-dose regimen of cyclophosphamide, doxorubicin, and fluorouracil) in the adjuvant trial. Eligibility requirements for enrollment in the larger trial included a radical mastectomy, modified radical mastectomy, or breast-conservation therapy within six weeks before initiation of the chemotherapy protocol; no prior chemotherapy or irradiation; a CALGB performance score of 0 or 1 (no symptoms or minimal symptoms); an age of at least 16 years; a white-cell count of 3500 or more per cubic millimeter and a platelet count of 100,000 or more per cubic millimeter; a hemoglobin level of 100 g or more per liter; blood urea nitrogen, serum creatinine, and bilirubin levels less than 1.5 times normal values; no concomitant cancer; and informed consent. Information on estrogen-receptor status was recorded at the time of enrollment in the study; standardization of estrogen- and progesterone-receptor assays was not required, but almost all participating institutions have certified laboratories meeting the requirements of the College of American Pathologists. For patients treated with lumpectomy or segmental mastectomy, a standardized irradiation protocol was administered after the completion of chemotherapy. All patients were followed in a standardized fashion after treatment to determine the frequency and rate of recurrent disease and overall survival.
Treatment
Patients were randomly assigned to receive cyclophosphamide, doxorubicin, and fluorouracil at one of three levels of dose intensity: 600 mg, 60 mg, and 600 mg per square meter of body-surface area, respectively, every four weeks for four cycles (group 1); 400 mg, 40 mg, and 400 mg per square meter every four weeks for six cycles (group 2); or 300 mg, 30 mg, and 300 mg per square meter every four weeks for four cycles (group 3). Fluorouracil was repeated on day 8 of each cycle. The cumulative doses of cyclophosphamide, doxorubicin, and fluorouracil were identical in groups 1 and 2 and 50 percent lower in group 3. The protocol was amended in April 1988 to require tamoxifen therapy (10 mg orally twice a day for five years) for all disease-free perimenopausal or postmenopausal patients who were positive for estrogen or progesterone receptors (≥ 7 fmol per milligram of protein). Tamoxifen was instituted after the completion of chemotherapy.
Specimen Preparation
Formalin-fixed, paraffin-embedded blocks from the primary breast lesions were obtained from participating CALGB institutions. A slide stained with hematoxylin and eosin was prepared from each block and used for pathological confirmation of breast cancer. From the same block, 4-micrometer tissue sections were prepared for immunohistochemical studies, and 50-micrometer sections for flow-cytometric analysis. All tumors were graded according to a nuclear grading system modified from that described by Black et al.33 and were histologically categorized by a reference pathologist without knowledge of the case.
Flow-Cytometric Analyses
All flow-cytometric analyses were performed in a single reference laboratory. The procedure of Hedley et al.,34 as modified by Kute et al.,8 was used to determine DNA content and cell-cycle kinetics. The 50-micrometer sections were deparaffinized, and flow cytometry was performed on malignant areas dissected from the specimen with the help of a tissue map (tumor enrichment). A diploid DNA standard was obtained from the nonmalignant tissue in the block, and the histogram for the DNA standard was compared with the histogram for the tumor-enriched area of the same block to correct for artifacts in fixation and preparation. The DNA index was obtained by comparing the ratio of the G1 peak channel of the malignant cells to that of the nonmalignant cells. Samples in which the G0G1 peaks of the diploid standard and the tumor did not match were not used for analysis. Three methods were used to analyze cell kinetics: the rectangular-fit model,35 a computer modeling procedure (Modfit)8 that determines G1, S, and G2 activity and corrects for variability in the coefficient of variation and the location of the peak channel, and an area-fit procedure. Only the Modfit model corrects for debris. The results of the three methods were closely correlated (data not shown); the rectangular-fit model was used in this analysis because the S-phase differences computed with this method provided the best correlation with prognosis. The relatively high median value of S-phase activity in the analysis is most likely related to the use of the rectangular-fit model. Flow-cytometric studies were performed without knowledge of information about the patients.
Immunohistochemical Analysis of c-erbB-2 Expression
All immunohistochemical analyses were performed in a single reference laboratory with the use of previously described methods31. Briefly, a polyclonal antibody (OA-11-854; Cambridge Research Biochemicals, Wilmington, Del.) reactive with the cytoplasmic domain of c-erbB-2 was used with avidin-biotin-peroxidase immunohistochemical methods. All slides were evaluated for c-erbB-2 overexpression by two investigators without knowledge of patient information. The percentage of stained invasive malignant cells was estimated, and tissue was considered to be positive for c-erbB-2 expression if any membranous activity was found in these cells at a magnification of 100. All malignant cells on each slide were evaluated. The two investigators had generally similar estimates of the frequency of stained cells on the slides (less than a 5 percent discrepancy between estimates). In a previous study, an immunohistochemical analysis of c-erbB-2 expression was shown to be closely correlated with HER-2/neu gene amplification36.
Immunohistochemical Analysis of p53 Expression
Expression of p53 was evaluated according to previously published methods24. Briefly, a monoclonal anti-p53 antibody (anti-p53 PAb1801; Cambridge Research Biochemicals) diluted 1:4000 was applied after the sections had been incubated overnight with diluted normal horse serum at 4 °C. The slides were rinsed and sequentially incubated with biotin-horse-antimouse and streptavidin-horseradish peroxidase (Zymed Laboratories, San Francisco). Diaminobenzidine (Sigma Chemical, St. Louis) was used to visualize antibody binding. Slides were counterstained with 1 percent aqueous methyl green, dehydrated, cleared, and mounted. For each assay, slides from fixed, embedded cell pellets from MDA-MB-231 (positive control) and HTB5 (negative control) (both from the American Type Culture Collection, Rockville, Md.) were included to ensure interassay consistency24. Two investigators evaluated each slide by light microscopy. If invasive tumor cells displayed nuclear brown staining, the slide was considered to be positive for p53 overexpression. An estimate was made of the percentage of positive invasive tumor cells visible at a magnification of 100.
Study Design and Statistical Analysis
At the time this trial was initiated, DNA content appeared to be the strongest flow-cytometric predictor of recurrent disease in patients with early-stage breast cancer37. A sample size of 134 patients per treatment group was estimated to have the capacity to detect a 25 percent difference in disease-free survival within each treatment group for patients whose tumors had aneuploid as compared with diploid DNA content (a power of 0.8 and a two-sided P value of 0.05). Blocks from a total of 442 patients were obtained for analysis. The demographic, clinicopathological, and laboratory variables we analyzed included treatment group, age at the time of enrollment in the study, menopausal status, tumor size, number of positive nodes, histologic type and grade, estrogen- and progesterone-receptor status, tamoxifen therapy, DNA content, S-phase fraction, c-erbB-2 expression, and p53 accumulation. We analyzed tumor size as a dichotomous variable ( ≤ 2 cm or >2 cm), as a continuous (linear) variable, and with square-root and logarithmic transformations. In both univariate and multivariate analyses, the dichotomous variables predicted overall and disease-free survival better than the other variables. Some variables were transformed to increase their predictive value. For example, we used the square root of the number of positive nodes, which performed better than the number of positive nodes in both linear and logarithmic scales. With the square-root transformation, an increase in the number of positive nodes from 1 to 4 carried about the same incremental risk as an increase in the number of positive nodes from 4 to 9 or from 9 to 16.
Overall survival was defined as the time from enrollment in the study to death; data on survivors were censored at the last follow-up visit. Disease-free survival was defined as the time from enrollment to a documented relapse or death without a relapse. Data on patients who did not have a relapse were censored at the last follow-up visit. To date, 98 of the 442 patients in this study have died, 95 of recurrent breast cancer. Survival curves were drawn according to the Kaplan-Meier product-limit method38-40. Two or more survival distributions were compared with the log-rank test. We used the Cox proportional-hazards model to relate the various covariables to disease-free and overall survival41. We used this method in univariate analyses to screen for prognostic variables and in multivariate analyses to identify sets of prognostic variables while controlling for the effects of other variables. This model assumes a constant ratio of hazard rates for different levels of therapy with prognostic variables. Categorical variables were compared with the chi-square test or Fisher's exact test. We used the Kruskal-Wallis test to compare variables across dose levels. Correlation coefficients were calculated to measure the association between pairs of variables that were potential predictors of survival.
Results
Patient Sample and Clinical Variables
Tissue blocks were obtained from 442 patients randomly selected from the 1572 patients enrolled in the adjuvant-chemotherapy trial. Of these 442 blocks, 397 (90 percent) were technically satisfactory for analysis of DNA content (ploidy) and c-erbB-2 expression, 394 (89 percent) for analysis of p53 expression, and 302 (68 percent) for analysis of the S-phase fraction. Aneuploid tumors were found in 59 percent of the patients, and the median S-phase fraction was 11 percent. At least some c-erbB-2 expression was found in 59 percent of the samples, and in 29 percent of the samples at least 50 percent of the cells stained for c-erbB-2. Some p53 expression was found in 42 percent of the samples, and in 17 percent of the samples 10 percent or more of the cells displayed p53 expression. This report includes follow-up data as of January 1, 1992. The median follow-up for all patients was 38.5 months, with a range of 1 week to 80 months.
Table 1Table 1
Characteristics of Patients with Node-Positive Early Breast Cancer. provides clinical data for the 442 patients in the three treatment groups, as well as for the total patient population. These data indicate that our sample was representative of the overall patient population. Patients in the three treatment groups had similar clinicopathological features except for histologic type; there were fewer infiltrating ductal carcinomas in group 3 than in groups 1 and 2 (87 percent vs. 95 and 97 percent, respectively). Although significant (P<0.01), this difference did not affect the outcome in either univariate or multivariate analyses. DNA content, c-erbB-2 expression, and p53 expression were similar among the three treatment groups (Table 2Table 2
DNA Content, S-Phase Fraction, and c-erbB-2 and p53 Expression.). There was a correlation between the S-phase fraction and c-erbB-2 expression (r = 0.13, P = 0.03) and between the S-phase fraction and p53 accumulation (r = 0.25, P<0.01).Disease-free and Overall Survival
The data from the larger CALGB trial at 3.2 years of follow-up showed that disease-free survival and overall survival in groups 1 and 2 (patients treated with high- or moderate-dose chemotherapy) were significantly longer than in group 3 (patients treated with low-dose chemotherapy)32. The data from the 442 patients in this analysis show a similar trend: a moderate- or high-dose regimen was associated with significantly longer disease-free survival (P<0.01) and overall survival (P = 0.13) (data not shown).
A univariate analysis demonstrated that the well-established clinical prognostic factors -- larger tumor size, higher number of positive nodes, higher tumor grade, and lack of estrogen and progesterone receptors -- were associated with shorter survival (Table 3Table 3
Results of Univariate Analyses of Overall and Disease-free Survival.). In contrast, older age and postmenopausal status were significantly associated with longer survival, and patients who received tamoxifen did better than those who did not receive this drug; tamoxifen, however, was administered to a select group of patients.Factors that were found to be significant in the univariate analysis (P<0.05), as well as c-erbB-2 expression, p53 accumulation, and S-phase fraction, were examined in the multivariate Cox model for their relation to disease-free and overall survival. Initially, we analyzed the results for the 269 patients whose tumor blocks were technically satisfactory for analyses of c-erbB-2 expression, p53 accumulation, S-phase fraction, and ploidy; the pretreatment characteristics of these patients and the 442 in the entire sample were similar (data not shown). This multivariate analysis revealed that a larger number of positive lymph nodes, a larger tumor size, premenopausal status, and greater c-erbB-2 expression were significant predictors of shorter disease-free and overall survival. In contrast, p53 accumulation was of marginal significance as a predictor of survival. Chemotherapy dose, age, histologic type and grade, estrogen- and progesterone-receptor status, and S-phase fraction were not predictors of either disease-free or overall survival.
By omitting the S-phase fraction from the model, we increased the sample size from 269 to 388 patients. Analysis of this group with the Cox model showed that all variables were significant predictors of survival except p53 accumulation and that menopausal status was no longer a significant factor for overall survival. A third multivariate analysis omitted both p53 accumulation and S-phase fraction (Table 4Table 4
Multivariate Analysis of Overall and Disease-free Survival (Cox Regression Model).). Again, the number of positive lymph nodes, tumor size, and c-erbB-2 expression were significantly related to both disease-free and overall survival. Moreover, there was a highly significant interaction between chemotherapy dose and c-erbB-2 expression for both disease-free and overall survival. Once the interaction between chemotherapy dose and c-erbB-2 expression had been accounted for, the interactions between the dose and the other variables did not provide additional predictive information. Replacing the S-phase fraction with histologic grade in the model did not give additional information. The dose of chemotherapy was not independently related to disease-free or overall survival in any of the models used in the multivariate analysis.Overexpression of c-erbB-2 as a Predictive Factor for Survival
Although a cutoff point is occasionally used to define a high- or low-risk group,37 this approach tends to oversimplify and even distort the relations between variables and outcomes. In the statistical modeling, we analyzed c-erbB-2 overexpression as a continuous variable. To portray these data graphically, however, we used a 50 percent cutoff point (Figure 1Figure 1
Disease-free and Overall Survival According to Treatment Group (High-Dose, Moderate-Dose, or Low-Dose Chemotherapy) and Level of c-erbB-2 Expression.). Patients whose tumors had 50 percent or more c-erbB-2 overexpression constituted 29 percent of the study population. Separation of the curves for both disease-free and overall survival in this group was both substantial and significant, indicating a dose-response effect (Figure 1C and Figure 1D). Notably, of the patients who were enrolled in group 1 of the adjuvant trial, those whose tumors overexpressed c-erbB-2 had longer disease-free and overall survival than those whose tumors did not overexpress c-erbB-2. In contrast, no dose-response effect was seen when the 71 percent of patients with no or low c-erbB-2 overexpression were grouped together. This relation between the dose-response effect and the c-erbB-2 level was relatively independent of other risk factors, such as the number of nodes involved. There was little difference in disease-free survival among the three treatment groups for patients whose tumors had no or low c-erbB-2 expression, regardless of the nodal status (Figure 1A and Figure 1B). Among those with a high level of overexpression, there was a significant dose-response effect for all nodal groups (data not shown).Discussion
This analysis of molecular markers in breast cancer suggests that increasing the dose intensity of adjuvant chemotherapy may not result in a similar benefit for all patients with positive nodes. It appears that patients whose tumors overexpress c-erbB-2 may derive the greatest benefit from higher doses of chemotherapy. In contrast, no benefit from dose intensification was observed in patients with no or low c-erbB-2 expression. These results should not be misconstrued to mean that lower doses of adjuvant therapy are not beneficial in patients with node-positive breast cancer. On the contrary, the results of an overview analysis suggest that combination chemotherapy significantly improves survival in such patients as compared with similar patients not receiving chemotherapy27.
Adjuvant chemotherapy appears to be more effective in patients whose tumors have a high thymidine-labeling index than in those whose tumors have a lower thymidine-labeling index30. Adjuvant chemotherapy has also been associated with improved disease-free and overall survival in patients with a higher tumor grade than in those with a lower tumor grade28,29. In a study of preoperative chemotherapy in patients with primary breast cancer, a high S-phase fraction was associated with a better response rate than a low S-phase fraction42. Similar correlations between the response to chemotherapy and the rate of tumor proliferation have been found in small cohorts of patients with locally advanced breast cancer43 or distant metastases44.
Two previous studies suggest that overexpression of c-erbB-2 may be associated with resistance to chemotherapy45,46. Both these studies used conventional doses of cyclophosphamide, methotrexate, and fluorouracil. In one of the studies, patients with node-negative breast cancer were randomly assigned to receive either six months of adjuvant chemotherapy or no chemotherapy at all45. Chemotherapy resulted in significantly longer disease-free survival among patients whose tumors did not express c-erbB-2 than among those with c-erbB-2 overexpression. In the other study, patients with positive nodes were randomly assigned to six months or one month of adjuvant chemotherapy. The longer period of therapy was associated with longer disease-free and overall survival46. However, among the patients who received six months of chemotherapy, disease-free survival was significantly longer among those whose tumors did not express c-erbB-2 than among those whose tumors overexpressed the oncogene.
What accounts for the differences between the results of these studies and our results? An important distinction is that our adjuvant-chemotherapy regimen included doxorubicin, whereas the regimens in the previous trials did not. Furthermore, c-erbB-2 expression may indeed be a marker of relative resistance to chemotherapy, but an escalation of the dose may overcome that resistance. Patients whose tumors overexpress c-erbB-2 may thus benefit from higher doses of chemotherapy given in regimens containing anthracyclines. On the other hand, patients whose tumors do not overexpress c-erbB-2 may not need higher doses of chemotherapy regimens that include anthracyclines to obtain the maximal benefit from adjuvant chemotherapy.
Doxorubicin is generally recognized as the most effective agent against breast cancer. It is possible that its efficacy is due in part to its ability to overcome the relative resistance to chemotherapy associated with c-erbB-2 overexpression. In a recent in vitro study, breast-cancer cells overexpressing c-erbB-2 frequently overexpressed topoisomerase IIalpha, a target enzyme for doxorubicin47. We are planning to measure the expression of topoisomerase II in available tissue specimens from patients in this study to determine whether c-erbB-2 expression is a marker for topoisomerase II expression through linkage. Tsai and colleagues have recently reported that increased resistance to the cytotoxicity of doxorubicin was directly related to increased c-erbB-2 expression in non-small-cell lung-cancer cell lines48. These data suggest that a high dose of doxorubicin may be necessary to kill tumor cells in patients with a high level of c-erbB-2 expression.
Expression of c-erbB-2 was significantly associated with treatment outcome in this trial, but it is not necessarily the ideal marker for predicting sensitivity to chemotherapy. Estimation of c-erbB-2 overexpression is imprecise, and no standardized assay is available. Estimates of c-erbB-2 expression are currently provided by many laboratories as part of a prognostic profile, but further data are needed before this marker can be used in making clinical decisions. Moreover, differences in assay and reporting methods make comparisons of our data and those of others tenuous.
Adjuvant chemotherapy prolongs disease-free and overall survival in patients with node-positive early breast cancer. However, the majority of patients with clinically occult metastases at the time of diagnosis ultimately have a relapse and die in spite of receiving a moderate-dose regimen of cyclophosphamide, doxorubicin, and fluorouracil or cyclophosphamide, methotrexate, and fluorouracil27. Trials are under way to determine whether high-dose chemotherapy with autologous bone marrow support improves the outcome for women with node-positive breast cancer. Such treatment involves substantial toxicity as well as a high cost49. Therefore, measurements that help identify those patients most likely to benefit from intensive treatment will be important. Data from other prospective trials are needed to corroborate our observations and determine whether either c-erbB-2 expression or other biologic markers can identify tumors that are particularly responsive or resistant to specific chemotherapeutic agents or to escalated doses of such agents.
Supported by grants (CA-03927, CA-44768, CA-31946, CA-33601, CA-47559, CA-07968, CA-12449, CA-37207, and CA-32291) from the National Cancer Institute.
Source Information
From the Bowman Gray School of Medicine, Winston-Salem, N.C. (H.B.M., T.K.); Massachusetts General Hospital, Boston (A.D.T., F.K.); the Statistical Office of the Cancer and Leukemia Group B, Durham, N.C. (D.A.B., C.T.C.); the Department of Medicine, University of North Carolina School of Medicine, Chapel Hill (E.T.L.); North Shore University Hospital (New York Hospital), New York (D.R.B.); Emory University, Atlanta (W.C.W.); the Department of Medicine, Roswell Park Memorial Institute, Buffalo, N.Y. (M.B.); and the University of California, San Francisco (I.C.H.).
Address reprint requests to Dr. Thor at the Department of Pathology, University of Vermont School of Medicine, Medical Alumni Bldg., Burlington, VT 05405.
- References
References
1
Carter CL ,Allen C ,Henson DE . Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-187
CrossRef | Web of Science | Medline2
Identification of breast cancer patients with high risk of early recurrence after radical mastectomyII. Clinical and pathological correlations: a report of the Primary Therapy of Breast Cancer Study Group. Cancer 1978;42:2809-2826
CrossRef | Web of Science | Medline3
Henson DE ,Ries L ,Freedman LS ,Carriaga M . Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer: the basis for a prognostic index. Cancer 1991;68:2142-2149
CrossRef | Web of Science | Medline4
Osborne CK. Receptors. In: Harris JR, Hellman S, Henderson IC, Kinne DW, eds. Breast diseases. 2nd ed. Philadelphia: J.B. Lippincott, 1991:301-25.
5
McGuire WL ,Clark GM . Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992;326:1756-1761
Full Text | Web of Science | Medline6
Muss HB, Kute TE. Flow cytometry in the management of breast cancer. In: Ragaz J, Ariel IM, eds. High-risk breast cancer: diagnosis. Berlin, Germany: Springer-Verlag, 1989:103-19.
7
Hedley DW ,Friedlander ML ,Taylor IW . Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry 1985;6:327-333
CrossRef | Medline8
Kute TE ,Gregory B ,Galleshaw J ,Hopkins M ,Buss D ,Case D . How reproducible are flow cytometry data from paraffin-embedded blocks? Cytometry 1988;9:494-498
CrossRef | Medline9
Slamon DJ ,Clark GM ,Wong SG ,Levin WJ ,Ullrich A ,McGuire WL . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
CrossRef | Web of Science | Medline10
Lupu R ,Colomer R ,Kannan B ,Lippman ME . Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. Proc Natl Acad Sci U S A 1992;89:2287-2291
CrossRef | Web of Science | Medline11
Harris AL ,Nicholson S ,Sainsbury R ,Wright C ,Farndon J . Epidermal growth factor receptor and other oncogenes as prognostic markers. Monogr Natl Cancer Inst 1992;11:181-187
Medline12
Barnes DM ,Meyer JS ,Gonzalez JG ,Gullick WJ ,Millis RR . Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. Breast Cancer Res Treat 1991;18:11-17
CrossRef | Web of Science | Medline13
Kallioniemi OP ,Holli K ,Visakorpi T ,Koivula T ,Helin HH ,Isola JJ . Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991;49:650-655
CrossRef | Web of Science | Medline14
Slamon DJ ,Godolphin W ,Jones LA , et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712
CrossRef | Web of Science | Medline15
Tandon AK ,Clark GM ,Chamness GC ,Ullrich A ,McGuire WL . HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-1128
Web of Science | Medline16
O'Reilly SM ,Barnes DM ,Camplejohn RS ,Bartkova J ,Gregory WM ,Richards MA . The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 1991;63:444-446
CrossRef | Web of Science | Medline17
Paik S ,Hazan R ,Fisher ER , et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8:103-112
Web of Science | Medline18
Toikkanen S ,Helin H ,Isola J ,Joensuu H . Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992;10:1044-1048
Web of Science | Medline19
Deppert W ,Buschhausen-Denker G ,Patschinsky T ,Steinmeyer K . Cell cycle control of p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. II. Requirement for cell cycle progression. Oncogene 1990;5:1701-1706
Web of Science | Medline20
Kern SE ,Kinzler KW ,Bruskin A , et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991;252:1708-1711
CrossRef | Web of Science | Medline21
Montenarh M . Biochemical, immunological, and functional aspects of the growth-suppressor/oncoprotein p53. Crit Rev Oncog 1992;3:233-256
Medline22
Shaw P ,Bovey R ,Tardy S ,Sahli R ,Sordat B ,Costa J . Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A 1992;89:4495-4499
CrossRef | Web of Science | Medline23
Callahan R ,Cropp CS ,Merlo GR ,Liscia DS ,Cappa APM ,Lidereau R . Somatic mutations and human breast cancer: a status report. Cancer 1992;69:Suppl:1582-1588
CrossRef | Web of Science | Medline24
Thor AD ,Moore DH II ,Edgerton SM , et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-855
CrossRef | Web of Science | Medline25
Isola J ,Visakorpi T ,Holli K ,Kallioniemi OP . Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992;84:1109-1114
CrossRef | Web of Science | Medline26
Allred DC ,Clark GM ,Elledge R , et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-206
CrossRef | Web of Science | Medline27
Early Breast Cancer Trialists' Collaborative Group
Web of Science | Medline28
Fisher ER ,Redmond C ,Fisher B . Pathologic findings from the National Surgical Adjuvant Breast Project. VIII. Relationship of chemotherapeutic responsiveness to tumor differentiation. Cancer 1983;51:181-191
CrossRef | Web of Science | Medline29
Fisher B ,Fisher ER ,Redmond C . Ten year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 1986;4:929-941
Web of Science | Medline30
Zambetti M ,Bonadonna G ,Valagussa P , et al. Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients. Monogr Natl Cancer Inst 1992;11:77-83
Medline31
O'Reilly SM ,Camplejohn RS ,Millis RR ,Rubens RD ,Richards MA . Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. Eur J Cancer 1990;26:1035-1038
CrossRef | Web of Science | Medline32
Wood WC ,Budman DR ,Korzun AH , et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-1259
Full Text | Web of Science | Medline33
Black MM ,Opler SR ,Speer FD . Survival in breast cancer cases in relation to the structure of the primary tumor and regional lymph nodes. Surg Gynecol Obstet 1955;100:543-551
Web of Science | Medline34
Hedley DW ,Friedlander ML ,Taylor IW ,Rugg CA ,Musgrove EA . Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983;31:1333-1335
CrossRef | Web of Science | Medline35
Baisch H ,Gohde W ,Linden WA . Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Radiat Environ Biophys 1975;12:31-39
CrossRef | Web of Science | Medline36
Liu E ,Thor A ,He M ,Barcos M ,Ljung BM ,Benz C . The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 1992;7:1027-1032
Web of Science | Medline37
Clark GM ,Dressler LG ,Owens MA ,Pounds G ,Oldaker T ,McGuire WL . Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989;320:627-633
Full Text | Web of Science | Medline38
Peto R ,Pike MC ,Armitage P , et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585-612
CrossRef | Web of Science | Medline39
Peto R ,Pike MC ,Armitage P , et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39
CrossRef | Web of Science | Medline40
Zar JH. Biostatistical analysis. Englewood Cliffs, N.J.: Prentice-Hall, 1974.
41
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22042
Remvikos Y ,Beuzeboc P ,Zajdela A ,Voillemot N ,Magdelenat H ,Pouillart P . Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 1989;81:1383-1387
CrossRef | Web of Science | Medline43
O'Reilly SM ,Camplejohn RS ,Rubens RD ,Richards MA . DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer 1992;28:681-683
CrossRef | Web of Science | Medline44
Sulkes A ,Livingston RB ,Murphy WK . Tritiated thymidine labeling index and response in human breast cancer. J Natl Cancer Inst 1979;62:513-515
Web of Science | Medline45
Allred DC ,Clark GM ,Tandon AK , et al. HER2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10:599-605
Web of Science | Medline46
Gusterson BA ,Gelber RD ,Goldhirsch A , et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;10:1049-1056
Web of Science | Medline47
Smith K ,Houlbrook S ,Greenall M ,Carmichael J ,Harris AL . Topoisomerase IIalpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 1993;8:933-938
Web of Science | Medline48
Tsai C-M ,Chang K-T ,Perng R-P , et al. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 1993;85:897-901
CrossRef | Web of Science | Medline49
Eddy DM . High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 1992;10:657-670[Erratum, J Clin Oncol 1992;10:1655-8.]
Web of Science | Medline
- Citing Articles (321)
Citing Articles
1
Nam Muk Oh, Dong Sup Kwag, Kyung Taek Oh, Yu Seok Youn, Eun Seong Lee. (2011) Electrostatic charge conversion processes in engineered tumor-identifying polypeptides for targeted chemotherapy. Biomaterials
CrossRef2
Yanan Kong, Shuqin Dai, Xinhua Xie, Xiangsheng Xiao, Ning Lv, Jiaoli Guo, Laisheng Li, Weihua Jia, Yin Zhang, Wanli Liu, Weidong Wei, Xiaoming Xie. (2011) High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. Journal of Cancer Research and Clinical Oncology
CrossRef3
Dipali Dhawan, Harish Padh. 2011. Omics Approaches in Cancer Biomarker and Targeted Anticancer Drug Discovery. , 333-358.
CrossRef4
Angelo Di Leo, Christine Desmedt, John M S Bartlett, Fanny Piette, Bent Ejlertsen, Kathleen I Pritchard, Denis Larsimont, Christopher Poole, Jorma Isola, Helena Earl, Henning Mouridsen, Frances P O'Malley, Fatima Cardoso, Minna Tanner, Alison Munro, Chris J Twelves, Christos Sotiriou, Lois Shepherd, David Cameron, Martine J Piccart, Marc Buyse. (2011) HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. The Lancet Oncology 12:12, 1134-1142
CrossRef5
Kathleen I. Pritchard, Alison Munro, Frances P. O’Malley, Dongsheng Tu, Xiao Li, Mark N. Levine, Lois Shepherd, Stephen Chia, John M. S. Bartlett. (2011) Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial. Breast Cancer Research and Treatment
CrossRef6
Slamon, Dennis, Eiermann, Wolfgang, Robert, Nicholas, Pienkowski, Tadeusz, Martin, Miguel, Press, Michael, Mackey, John, Glaspy, John, Chan, Arlene, Pawlicki, Marek, Pinter, Tamas, Valero, Vicente, Liu, Mei-Ching, Sauter, Guido, von Minckwitz, Gunter, Visco, Frances, Bee, Valerie, Buyse, Marc, Bendahmane, Belguendouz, Tabah-Fisch, Isabelle, Lindsay, Mary-Ann, Riva, Alessandro, Crown, John, . (2011) Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine 365:14, 1273-1283
Full Text7
Monica N. Fornier. (2011) Anthracyclines in the adjuvant treatment of breast cancer: state of the art. European Journal of Cancer Supplements 9:2, 5-10
CrossRef8
K Pandya, K Meeke, A G Clementz, A Rogowski, J Roberts, L Miele, K S Albain, C Osipo. (2011) Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. British Journal of Cancer 105:6, 796-806
CrossRef9
Alexandra Giatromanolaki, Efthimios Sivridis, Aliki Fiska, Michael I. Koukourakis. (2011) The CD44+/CD24− phenotype relates to ‘triple-negative’ state and unfavorable prognosis in breast cancer patients. Medical Oncology 28:3, 745-752
CrossRef10
L. Yao, Y. Liu, Z. Li, T. Ouyang, J. Li, T. Wang, Z. Fan, T. Fan, B. Lin, Y. Xie. (2011) HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Annals of Oncology 22:6, 1326-1331
CrossRef11
William C. Wood. (2011) Cooperation in Clinical Trials. Journal of the American College of Surgeons 212:4, 431-439
CrossRef12
Henry L. Gómez, Joseph A. Pinto, Mivael Olivera, Tatiana Vidaurre, Franco D. Doimi, Carlos E. Vigil, Raúl G. Velarde, Julio E. Abugattas, Edith Alarcón, Carlos S. Vallejos. (2011) Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer. The Breast 20:1, 39-45
CrossRef13
Ashley Davidson, Karen Gelmon. (2011) Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?. Future Oncology 7:1, 37-55
CrossRef14
Sejal Shah, Beiyun Chen. (2011) Testing for HER2 in Breast Cancer: A Continuing Evolution. Pathology Research International 2011, 1-16
CrossRef15
K.P.S. Raghav, A.M. Gonzalez-Angulo. (2011) Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Breast Diseases: A Year Book Quarterly 22:2, 156-158
CrossRef16
Dong-Youl Choi, Ran Hong, Sung-Churl Lim, Keun-Hong Kee, Chae-Hong Suh, Mija Lee. (2011) Prognostic Implications of the Expression of CXCL16 in Breast Carcinoma. The Korean Journal of Pathology 45:1, 15
CrossRef17
Cathy Maxwell. (2010) Biomarker Research in Breast Cancer. Clinical Journal of Oncology Nursing 14:6, 771-783
CrossRef18
A F Munro, D A Cameron, J M S Bartlett. (2010) Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge. Oncogene 29:38, 5231-5240
CrossRef19
Efthimios Sivridis, Charilaos Stamos, Aliki Fiska, Nikolaos Nikolettos, Michael I. Koukourakis, Alexandra Giatromanolaki. (2010) c-erbB-2 and the “triple-state” in early breast carcinomas. Medical Oncology 27:3, 578-584
CrossRef20
A-Hyeong Lee, Kyung-Taek Oh, Hye-Jung Baik, Bo-Reum Lee, Young-Taik Oh, Don-Haeng Lee, Eun-Seong Lee. (2010) Development of Worm-like Polymeric Drug Carriers with Multiple Ligands for Targeting Heterogeneous Breast Cancer Cells. Bulletin of the Korean Chemical Society 31:8, 2265-2271
CrossRef21
I. Craig Henderson. (2010) Adjuvant chemotherapy is not for everyone. Breast Cancer Research and Treatment 123:1, 159-162
CrossRef22
Catherine M. Kelly, Gabriel N. Hortobagyi. (2010) Adjuvant Chemotherapy in Early-Stage Breast Cancer: What, When, and for Whom?. Surgical Oncology Clinics of North America 19:3, 649-668
CrossRef23
Ellis, Matthew, . (2010) Taxane-Based Chemotherapy for Node-Positive Breast Cancer — Take-Home Lessons. New England Journal of Medicine 362:22, 2122-2124
Full Text24
Per E. Lønning. (2010) Molecular basis for therapy resistance. Molecular Oncology 4:3, 284-300
CrossRef25
Nam Muk Oh, Kyung Taek Oh, Hye Jung Baik, Bo Reum Lee, A. Hyeong Lee, Yu Seok Youn, Eun Seong Lee. (2010) A self-organized 3-diethylaminopropyl-bearing glycol chitosan nanogel for tumor acidic pH targeting: In vitro evaluation. Colloids and Surfaces B: Biointerfaces 78:1, 120-126
CrossRef26
Efthimios Sivridis, Michael I. Koukourakis, Christos E. Zois, Ioanna Ledaki, David J.P. Ferguson, Adrian L. Harris, Kevin C. Gatter, Alexandra Giatromanolaki. (2010) LC3A-Positive Light Microscopy Detected Patterns of Autophagy and Prognosis in Operable Breast Carcinomas. The American Journal of Pathology 176:5, 2477-2489
CrossRef27
Gottfried E. Konecny, Giovanni Pauletti, Michael Untch, He-Jing Wang, Volker Möbus, Walther Kuhn, Christoph Thomssen, Nadia Harbeck, Ling Wang, Sophia Apple, Fritz Jänicke, Dennis J. Slamon. (2010) Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer. Breast Cancer Research and Treatment 120:2, 481-489
CrossRef28
Jun-Hua Peng, Jun-Dong Zhu, Man-Tian Mi, Fu-Jun Li, Lin Cai, Ju-Zi Dong, Hua-Xin Zhang, Yong Zhao, Rong-Li Xue. (2010) Prepubertal genistein exposure affects erbB2/Akt signal and reduces rat mammary tumorigenesis. European Journal of Cancer Prevention 19:2, 110-119
CrossRef29
April Davoli, Barbara A. Hocevar, Thomas L. Brown. (2010) Progression and treatment of HER2-positive breast cancer. Cancer Chemotherapy and Pharmacology 65:4, 611-623
CrossRef30
Emanuel Raschi, Valentina Vasina, Maria Grazia Ursino, Giuseppe Boriani, Andrea Martoni, Fabrizio De Ponti. (2010) Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. Pharmacology & Therapeutics 125:2, 196-218
CrossRef31
Bas J. M. Peters, Andrei S. Rodin, Anthonius De Boer, Anke-Hilse Maitland-van der Zee. (2010) Methodological and statistical issues in pharmacogenomics. Journal of Pharmacy and Pharmacology 62:2, 161-166
CrossRef32
Felipe C. Geyer, Maria A. Lopez-Garcia, Maryou B. Lambros, Jorge S. Reis-Filho. (2009) Genetic characterization of breast cancer and implications for clinical management. Journal of Cellular and Molecular Medicine 13:10, 4090-4103
CrossRef33
Hasan Senol COSKUN, Mustafa ALTINBAS, Ozlem ER, Figen OZTURK, Hatice KARAMAN, Serdar SOYUER, Metin OZKAN, Isin SOYUER. (2009) Human epidermal growth factor receptor 2 oncoprotein expression in breast cancer patients from central Anatolia, Turkey. Asia-Pacific Journal of Clinical Oncology 5:3, 206-211
CrossRef34
Tsz-Kok YAU, Ting-Ying NG, Inda Sung SOONG, Chi-Wai CHOI, ka-On LAM, Alice Wan-Ying NG, Anne Wing-Mui LEE, Yuk TUNG. (2009) Toxicity of docetaxel plus cyclophosphamide as adjuvant therapy for breast cancer in Chinese patients - the Hong Kong experience. Asia-Pacific Journal of Clinical Oncology 5:2, 123-128
CrossRef35
D. J. Slamon, M. F. Press. (2009) Alterations in the TOP2A and HER2 Genes: Association With Adjuvant Anthracycline Sensitivity in Human Breast Cancers. JNCI Journal of the National Cancer Institute 101:9, 615-618
CrossRef36
Phuong Khanh H. Morrow, Gabriel N. Hortobagyi. (2009) Management of Breast Cancer in the Genome Era. Annual Review of Medicine 60:1, 153-165
CrossRef37
DEBRA HAWES, SHAN-RONG SHI, DAVID J. DABBS, CLIVE R. TAYLOR, RICHARD J. COTE. 2009. Immunohistochemistry. , 48-70.
CrossRef38
Eun Seong Lee, Zhonggao Gao, You Han Bae. (2008) Recent progress in tumor pH targeting nanotechnology. Journal of Controlled Release 132:3, 164-170
CrossRef39
Federico Rojo, Joan Albanell, Ana Rovira, Josep Maria Corominas, Felix Manzarbeitia. (2008) Targeted therapies in breast cancer. Seminars in Diagnostic Pathology 25:4, 245-261
CrossRef40
Christoph Oehler-Jänne, André O. von Bueren, Van Vuong, Andreas Hollenstein, Michael A. Grotzer, Martin Pruschy. (2008) Temperature sensitivity of phospho-Ser473-PKB/AKT. Biochemical and Biophysical Research Communications 375:3, 399-404
CrossRef41
Manuel Comabella. (2008) Pharmacogenomics in multiple sclerosis: getting the right medicine to the right patient. Therapy 5:5, 623-629
CrossRef42
C Osipo, P Patel, P Rizzo, A G Clementz, L Hao, T E Golde, L Miele. (2008) ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitor. Oncogene 27:37, 5019-5032
CrossRef43
Eun Seong Lee, Zhonggao Gao, Dongin Kim, Kyeongsoon Park, Ick Chan Kwon, You Han Bae. (2008) Super pH-sensitive multifunctional polymeric micelle for tumor pHe specific TAT exposure and multidrug resistance. Journal of Controlled Release 129:3, 228-236
CrossRef44
M Spears, J Kenicer, A F Munro, JMS Bartlett. (2008) Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer. Biomarkers in Medicine 2:4, 397-407
CrossRef45
A. Gennari, M. P. Sormani, P. Pronzato, P. Bruzzi. (2008) Response:Re: HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials. JNCI Journal of the National Cancer Institute 100:9, 680-681
CrossRef46
Stacey Williams, Colleen Ryan, Christian Jacobson. (2008) Agrin and neuregulin, expanding roles and implications for therapeutics. Biotechnology Advances 26:3, 187-201
CrossRef47
Edurne Arriola, Caterina Marchio, David SP Tan, Suzanne C Drury, Maryou B Lambros, Rachael Natrajan, Socorro Maria Rodriguez-Pinilla, Alan Mackay, Narinder Tamber, Kerry Fenwick, Chris Jones, Mitch Dowsett, Alan Ashworth, Jorge S Reis-Filho. (2008) Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Laboratory Investigation 88:5, 491-503
CrossRef48
A. Gennari, M. P. Sormani, P. Pronzato, M. Puntoni, M. Colozza, U. Pfeffer, P. Bruzzi. (2008) HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials. JNCI Journal of the National Cancer Institute 100:1, 14-20
CrossRef49
S. Paik, Y. Taniyama, C. E. Geyer. (2008) Anthracyclines in the Treatment of HER2-Negative Breast Cancer. JNCI Journal of the National Cancer Institute 100:1, 2-4
CrossRef50
Patrick J Perik, Maarten Alexander de Korte, Dirk J van Veldhuisen, Jourik A Gietema, Dirk T Sleijfer, Elisabeth GE de Vries. (2007) Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Expert Review of Anticancer Therapy 7:12, 1763-1771
CrossRef51
Lenka Krsková, Marketa Kalinová, Helena Břizová, Marcela Mrhalová, David Sumerauer, Roman Kodet. (2007) Molecular and Immunohistochemical Analysis of ERBB2 Expression in Correlation With Proliferation Rate in Synovial Sarcoma. Diagnostic Molecular Pathology 16:4, 211-217
CrossRef52
Edurne Arriola, Socorro Maria Rodriguez-Pinilla, Maryou B. K. Lambros, Robin L. Jones, Michelle James, Kay Savage, Ian E. Smith, Mitch Dowsett, Jorge S. Reis-Filho. (2007) Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Research and Treatment 106:2, 181-189
CrossRef53
Hayes, Daniel F., Thor, Ann D., Dressler, Lynn G., Weaver, Donald, Edgerton, Susan, Cowan, David, Broadwater, Gloria, Goldstein, Lori J., Martino, Silvana, Ingle, James N., Henderson, I. Craig, Norton, Larry, Winer, Eric P., Hudis, Clifford A., Ellis, Matthew J., Berry, Donald A., . (2007) HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. New England Journal of Medicine 357:15, 1496-1506
Full Text54
Iris Grossman. (2007) Routine pharmacogenetic testing in clinical practice: dream or reality?. Pharmacogenomics 8:10, 1449-1459
CrossRef55
Tanuja Shet, Atin Agrawal, Roshni Chinoy, Rohini Havaldar, Vani Parmar, Rajan Badwe. (2007) Changes in the Tumor Grade and Biological Markers in Locally Advanced Breast Cancer after Chemotherapy ? Implications for a Pathologist. The Breast Journal 13:5, 457-464
CrossRef56
Yong Wha Moon, Hei-Cheul Jeung, Sun Young Rha, Yeon Ho Choi, Woo Ick Yang, Hyun Cheol Chung. (2007) Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer. Breast Cancer Research and Treatment 104:1, 31-37
CrossRef57
Catalina Falo, Abelardo Moreno, Mar Varela, Belen Lloveras, Agnès Figueras, Agustín Escobedo. (2007) HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy. Journal of Cancer Research and Clinical Oncology 133:7, 423-429
CrossRef58
Josie Ursini-Siegel, Babette Schade, Robert D. Cardiff, William J. Muller. (2007) Insights from transgenic mouse models of ERBB2-induced breast cancer. Nature Reviews Cancer 7:5, 389-397
CrossRef59
Bolin Liu, Dalia Ordonez-Ercan, Zeying Fan, Susan M. Edgerton, XiaoHe Yang, Ann D. Thor. (2007) Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. International Journal of Cancer 120:9, 1874-1882
CrossRef60
Torun Engfeldt, Anna Orlova, Thuy Tran, Alexander Bruskin, Charles Widström, Amelie Eriksson Karlström, Vladimir Tolmachev. (2007) Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. European Journal of Nuclear Medicine and Molecular Imaging 34:5, 722-733
CrossRef61
Frances M. Palmieri, Edith A. Perez. (2007) Managing High-Risk Breast Cancer. Seminars in Oncology Nursing 23:1, 29-36
CrossRef62
Gianluigi Ferretti, Alessandra Felici, Paola Papaldo, Alessandra Fabi, Francesco Cognetti. (2007) HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Current Opinion in Obstetrics and Gynecology 19:1, 56-62
CrossRef63
J. M. Liu, L. S. Wang, M. H. Huang, W. H. Hsu, S. H. Yen, C. Y. Shiau, A. F. Y. Li, C. M. Tiu, S. W. Tseng, B. S. Huang. (2007) Topoisomerase 2α plays a pivotal role in the tumor biology of stage IV thymic neoplasia. Cancer 109:3, 502-509
CrossRef64
Emma Niméus, Johan Malmström, Anders Johnsson, György Marko-Varga, Mårten Fernö. (2007) Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy. Journal of Pharmaceutical and Biomedical Analysis 43:3, 1086-1093
CrossRef65
Canfeza Sezgin, Ender Kurt, Turkan Evrensel, Necmettin Ozdemir, Osman Manavoglu, Erdem Goker. (2007) Efficacy of Lower Dose Capecitabine in Patients with Metastatic Breast Cancer and Factors Influencing Therapeutic Response and Outcome. Southern Medical Journal 100:1, 27-32
CrossRef66
Jennifer Laudadio, Denise I Quigley, Raymond Tubbs, Daynna J Wolff. (2007) HER2 testing: a review of detection methodologies and their clinical performance. Expert Review of Molecular Diagnostics 7:1, 53-64
CrossRef67
J Hannemann, P Kristel, H van Tinteren, M Bontenbal, Q G C M van Hoesel, W M Smit, M A Nooij, E E Voest, E van der Wall, P Hupperets, E G E de Vries, S Rodenhuis, M J van de Vijver. (2006) Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy. British Journal of Cancer 95:10, 1334-1341
CrossRef68
Anna Bergamaschi, Young H. Kim, Pei Wang, Therese Sørlie, Tina Hernandez-Boussard, Per E. Lonning, Robert Tibshirani, Anne-Lise Børresen-Dale, Jonathan R. Pollack. (2006) Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes, Chromosomes and Cancer 45:11, 1033-1040
CrossRef69
J.A. VILLELLA, S. COHEN, D.H. SMITH, H. HIBSHOOSH, D. HERSHMAN. (2006) HER-2/ neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. International Journal of Gynecological Cancer 16:5, 1897-1902
CrossRef70
Eriko Tokunaga, Eiji Oki, Kojiro Nishida, Tadashi Koga, Akinori Egashira, Masaru Morita, Yoshihiro Kakeji, Yoshihiko Maehara. (2006) Trastuzumab and breast cancer: developments and current status. International Journal of Clinical Oncology 11:3, 199-208
CrossRef71
Erich F. Solomayer, Sven Becker, Graziella Pergola-Becker, Robert Bachmann, Bernhard Krämer, Ulrich Vogel, Hans Neubauer, Diethelm Wallwiener, Jens Huober, Tanja N. Fehm. (2006) Comparison of HER2 status between primary tumor and disseminated tumor cells in
primary breast cancer patients. Breast Cancer Research and Treatment 98:2, 179-184
CrossRef72
Hitoshi Tsuda. (2006) HER-2 (c-erbB-2) test update: Present status and problems. Breast Cancer 13:3, 236-248
CrossRef73
K Park, S Han, H J Kim, J Kim, E Shin. (2006) HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 48:6, 702-707
CrossRef74
Rita Nahta, Dihua Yu, Mien-Chie Hung, Gabriel N Hortobagyi, Francisco J Esteva. (2006) Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clinical Practice Oncology 3:5, 269-280
CrossRef75
Ioannis Kostopoulos, Petroula Arapantoni-Dadioti, Helen Gogas, Savvas Papadopoulos, Vasiliki Malamou-Mitsi, Chrisoula D. Scopa, Sofia Markaki, Evangelia Karagianni, Vasiliki Kyriakou, Anastasia Margariti, Elisavet Kyrkou, Kitty Pavlakis, Thomas Zaramboukas, Anna Skordalaki, Antonia Bourli, Christos Markopoulos, Dimitrios Pectasides, Meletios A. Dimopoulos, Dimosthenis Skarlos, George Fountzilas. (2006) Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose–dense sequential adjuvant chemotherapy. Breast Cancer Research and Treatment 96:3, 251-261
CrossRef76
Susan Peck, Joyce A. O'Shaughnessy. (2006) Molecular Insights from the 2005 San Antonio Breast Cancer Symposium. Clinical Breast Cancer 7:1, 29-32
CrossRef77
Cecilia Bozzetti, Antonino Musolino, Roberta Camisa, Giancarlo Bisagni, Marcella Flora, Cristina Bassano, Eugenia Martella, Costanza Lagrasta, Rita Nizzoli, Nicola Personeni, Francesco Leonardi, Giorgio Cocconi, Andrea Ardizzoni. (2006) Evaluation of HER-2/Neu Amplification and Other Biological Markers as Predictors of Response to Neoadjuvant Anthracycline-Based Chemotherapy in Primary Breast Cancer. American Journal of Clinical Oncology 29:2, 171-177
CrossRef78
Charles H Yang, Massimo Cristofanilli. (2006) The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer. Future Oncology 2:2, 247-255
CrossRef79
Agostinho Pinto Gouv??a, Fernanda Milanezi, Sandra Jean Olson, Dina Leitao, Fernando Carlos Schmitt, Helenice Gobbi. (2006) Selecting Antibodies to Detect HER2 Overexpression by Immunohistochemistry in Invasive Mammary Carcinomas. Applied Immunohistochemistry & Molecular Morphology 14:1, 103-108
CrossRef80
Rita Nahta, Francisco J. Esteva. (2006) Herceptin: mechanisms of action and resistance. Cancer Letters 232:2, 123-138
CrossRef81
Soo-kyung Ahn, Keumhee Kwak, Eunah Shin, Hyunjung Kim, Jungyeon Kim, Kyeongmee Park, Sehwan Han. (2006) Correlation between C-MYC and HER2 Amplification in Non-selected Breast Cancers. Journal of Breast Cancer 9:3, 200
CrossRef82
Ronan A. Cahill, Daniel Walsh, Rob J. Landers, R. Gordon Watson. (2006) Preoperative Profiling of Symptomatic Breast Cancer by Diagnostic Core Biopsy. Annals of Surgical Oncology 13:1, 45-51
CrossRef83
N. U. Lin, R. Gelman, E. P. Winer. (2005) Dose Density in Breast Cancer: A Simple Message?. JNCI Journal of the National Cancer Institute 97:23, 1712-1714
CrossRef84
Maria D. Corte, Juan A. Rodil, Julio Vázquez, Lucia García, Juan C. Rodríguez, Miguel Bongera, José C. Fernández, Luis O. González, Ma Luz Lamelas, Maite Allende, José L. García-Muñiz, Antonio Fueyo, Francisco J. Vizoso. (2005) Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA). Journal of Cancer Research and Clinical Oncology 131:11, 701-714
CrossRef85
Amy L Lark, Chad A Livasy, Lynn Dressler, Dominic T Moore, Robert C Millikan, Joseph Geradts, Mary Iacocca, David Cowan, Debbie Little, Rolf J Craven, William Cance. (2005) High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Modern Pathology 18:10, 1289-1294
CrossRef86
Kelly K. Hunt, Khandan Keyomarsi. (2005) Cyclin E as a prognostic and predictive marker in breast cancer. Seminars in Cancer Biology 15:4, 319-326
CrossRef87
Eskender Mume, Anna Orlova, Per-Uno Malmström, Hans Lundqvist, Stefan Sjöberg, Vladimir Tolmachev. (2005) Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET. Nuclear Medicine and Biology 32:6, 613-622
CrossRef88
G. Arpino, D. R. Ciocca, H. Weiss, D. C. Allred, P. Daguerre, L. Vargas-Roig, M. Leuzzi, F. Gago, R. Elledge, S. K. Mohsin. (2005) Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Research and Treatment 92:1, 69-75
CrossRef89
Kyeongmee Park, Keumhee Kwak, Jungyeon Kim, Sungjig Lim, Sehwan Han. (2005) c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers. Human Pathology 36:6, 634-639
CrossRef90
Sam M. Wiseman, Nikita Makretsov, Torsten O. Nielsen, Blake Gilks, Erika Yorida, Maggie Cheang, Dmitry Turbin, Karen Gelmon, David G. Huntsman. (2005) Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 103:9, 1770-1777
CrossRef91
Yun Gong, Daniel J. Booser, Nour Sneige. (2005) Comparison ofHER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 103:9, 1763-1769
CrossRef92
Avina Kapoor, Victor G Vogel. (2005) Prognostic factors for breast cancer and their use in the clinical setting. Expert Review of Anticancer Therapy 5:2, 269-281
CrossRef93
Dafydd G. Thomas, Thomas J. Giordano, Donita Sanders, Sybil Biermann, Vernon K. Sondak, Jonathan C. Trent, Dihua Yu, Raphael E. Pollock, Laurence Baker. (2005) Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 103:4, 830-838
CrossRef94
Shaker Abuharbeid, J
rgen Apel, Gerhard Zugmaier, Cornelius Knabbe, Martin Sander, Sandra Gilbert, Frank Czubayko, Achim Aigner. (2005) Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. Naunyn-Schmiedeberg's Archives of Pharmacology 371:2, 141-151
CrossRef95
Sabarni K Chatterjee, Bruce R Zetter. (2005) Cancer biomarkers: knowing the present and predicting the future. Future Oncology 1:1, 37-50
CrossRef96
R J Burcombe, A Makris, P I Richman, F M Daley, S Noble, M Pittam, D Wright, S A Allen, J Dove, G D Wilson. (2005) Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. British Journal of Cancer 92:1, 147-155
CrossRef97
Maureen E. Trudeau, Kathleen I. Pritchard, Judy-Anne W. Chapman, Wedad M. Hanna, Harriette J. Kahn, David Murray, Carol A. Sawka, Betty G. Mobbs, Irene Andrulis, David R. McCready, H. Lavina Lickley. (2005) Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Research and Treatment 89:1, 35-45
CrossRef98
Per Eystein L
CrossRef99
Nicholas J. Robert, Charles L. Vogel, I. Craig Henderson, Joseph A. Sparano, Melvin R. Moore, Paula Silverman, Beth A. Overmoyer, Charles L. Shapiro, John W. Park, Gail T. Colbern, Eric P. Winer, Alberto A. Gabizon. (2004) The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Seminars in Oncology 31, 106-146
CrossRef100
John W. Park, Christopher C. Benz, Francis J. Martin. (2004) Future directions of liposome- and immunoliposome-based cancer therapeutics. Seminars in Oncology 31, 196-205
CrossRef101
Mohammed Kashani-Sabet. (2004) Non-viral delivery of ribozymes for cancer gene therapy. Expert Opinion on Biological Therapy 4:11, 1749-1755
CrossRef102
Reda S Saad, Yulin Liu, Helen Han, Rodney J Landreneau, Jan F Silverman. (2004) Prognostic significance of HER2/neu, p53, and vascular endothelial growth factor expression in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Modern Pathology 17:10, 1235-1242
CrossRef103
X Sastre-Garau, P Genin, A Rousseau, A Al Ghuzlan, A Nicolas, P Freneaux, C Rosty, B Sigal-Zafrani, J Couturier, J-P Thiery, H Magdelenat, A Vincent-Salomon. (2004) Increased cell size and Akt activation in HER-2/neu-overexpressing invasive ductal carcinoma of the breast. Histopathology 45:2, 142-147
CrossRef104
Barbara G. Beatty, Ronald Bryant, Weichen Wang, Takamaru Ashikaga, Pamela C. Gibson, Gladwyn Leiman, Donald L. Weaver. (2004) HER-2/neu Detection in Fine-Needle Aspirates of Breast Cancer Fluorescence In Situ Hybridization and Immunocytochemical Analysis. American Journal of Clinical Pathology 122:2, 246-255
CrossRef105
Volkmar Müller, Isabell Witzel, Hans Joachim Lück, Günter Köhler, Gunther von Minckwitz, Volker Möbus, Daniel Sattler, Waldemar Wilczak, Thomas Löning, Fritz Jänicke, Klaus Pantel, Christoph Thomssen. (2004) Prognostic and Predictive Impact of the HER-2/neu Extracellular Domain (ECD) in the Serum of Patients Treated with Chemotherapy for Metastatic Breast Cancer. Breast Cancer Research and Treatment 86:1, 9-18
CrossRef106
F Miyazono, R Metzger, U Warnecke-Eberz, S E Baldus, J Brabender, E Bollschweiler, W Doerfler, R P Mueller, H P Dienes, T Aikou, A H Hoelscher, P M Schneider. (2004) Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. British Journal of Cancer
CrossRef107
Michel Vulfovich, Nabil Saba. (2004) Molecular biological design of novel antineoplastic therapies. Expert Opinion on Investigational Drugs 13:6, 577-607
CrossRef108
Toshiaki Moriki, Tamotsu Takahashi, Shousuke Ueta, Miko Mitani, Miho Ichien. (2004) Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: Correlation with histologic sections determinations and diagnostic pitfalls. Diagnostic Cytopathology 30:4, 251-256
CrossRef109
M Parton, M Dowsett, S Ashley, M Hills, F Lowe, I.E Smith. (2004) High incidence of HER-2 positivity in inflammatory breast cancer. The Breast 13:2, 97-103
CrossRef110
Vasil Punj, Jewell M. Graves, Rajeshwari R. Mehta. (2004) Effect of vitamin D analog (1? hydroxy D5) immunoconjugated to Her-2 antibody on breast cancer. International Journal of Cancer 108:6, 922-929
CrossRef111
Alexandra Giatromanolaki, Michael I. Koukourakis, Stelios Kakolyris, Dimitris Mavroudis, Charalambos Kouroussis, Chrysa Mavroudi, Maria Perraki, Efthimios Sivridis, Vassilis Georgoulias. (2004) Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. International Journal of Cancer 108:4, 620-627
CrossRef112
Christophe Rosty, J??r??me Couturier, Anne Vincent-Salomon, Pascal Genin, Paul Fr??neaux, Brigitte Sigal-Zafrani, Xavier Sastre-Garau. (2004) Overexpression/Amplification of HER-2/neu is Uncommon in Invasive Carcinoma of the Uterine Cervix. International Journal of Gynecological Pathology 23:1, 13-17
CrossRef113
Masakazu Toi, Masahiro Takada, Hiroko Bando, Kazumi Toyama, Hiroyasu Yamashiro, Shinichiro Horiguchi, Shigehira Saji. (2004) Current status of antibody therapy for breast cancer. Breast Cancer 11:1, 10-14
CrossRef114
Dolly Varshney, Yvonne Y. Zhou, Stephen A. Geller, Randa Alsabeh. (2004) Determination of HER-2 Status and Chromosome 17 Polysomy in Breast Carcinomas Comparing HercepTest and PathVysion FISH Assay. American Journal of Clinical Pathology 121:1, 70-77
CrossRef115
Catalina Falo, Abelardo Moreno, Belen Lloveras, Agn??s Figueras, Mar Varela, Agust??n Escobedo. (2003) Algorithm for the Diagnosis of HER-2/ neu Status in Breast-Infiltrating Carcinomas. American Journal of Clinical Oncology 26:5, 465-470
CrossRef116
Wentao Yang, Kristine S. Klos, Xiaoyan Zhou, Jun Yao, Ying Yang, Terry L. Smith, Daren Shi, Dihua Yu. (2003) ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2. Cancer 98:6, 1123-1130
CrossRef117
Jo Anne Zujewski, Jennifer Eng-Wong, Joyce O'Shaughnessy, David Venzon, Catherine Chow, David Danforth, David R. Kohler, Georgia Cusack, David Riseberg, Kenneth H. Cowan. (2003) A Pilot Study of Dose Intense Doxorubicin and Cyclophosphamide Followed by Infusional Paclitaxel in High-Risk Primary Breast Cancer. Breast Cancer Research and Treatment 81:1, 41-51
CrossRef118
Geza Acs, Lynn Wang, Puthiyaveettil N. Raghunath, Marilyn A. Salscheider, Paul J. Zhang. (2003) Role of Different Immunostaining Patterns in HercepTest Interpretation and Criteria for Gene Amplification as Determined by Fluorescence In Situ Hybridization. Applied Immunohistochemistry & Molecular Morphology222-229
CrossRef119
S. M. Edgerton, D. Moore,, D. Merkel, Ann D. Thor. (2003) erbB-2 (HER-2) and Breast Cancer Progression. Applied Immunohistochemistry & Molecular Morphology214-221
CrossRef120
Priti Lal, Paulo A. Salazar, Marc Ladanyi, Beiyun Chen. (2003) Impact of Polysomy 17 on HER-2/neu Immunohistochemistry in Breast Carcinomas without HER-2/neu Gene Amplification. The Journal of Molecular Diagnostics 5:3, 155-159
CrossRef121
Giorgio Cocconi. (2003) Adjuvant Chemotherapy in Early Breast Cancer: Optimal and Suboptimal Anthracycline-Containing Regimens. Breast Cancer Research and Treatment 80:3, 313-320
CrossRef122
Rodenhuis, Sjoerd, Bontenbal, Marijke, Beex, Louk V.A.M., Wagstaff, John, Richel, Dick J., Nooij, Marianne A., Voest, Emile E., Hupperets, Pierre, van Tinteren, Harm, Peterse, Hans L., TenVergert, Elisabeth M., de Vries, Elisabeth G.E., . (2003) High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer. New England Journal of Medicine 349:1, 7-16
Full Text123
Paolo Giovanni Nuciforo, Caterina Pellegrini, Roberta Fasani, Marco Maggioni, Guido Coggi, Antonina Parafioriti, Silvano Bosari. (2003) Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. Human Pathology 34:7, 639-645
CrossRef124
Manuela Campiglio, Giulia Somenzi, Clelia Olgiati, Giovanni Beretta, Andrea Balsari, Nadia Zaffaroni, Pinuccia Valagussa, Sylvie M
CrossRef125
S. Rodenhuis. (2003) Chemotherapie mammacarcinoom. Bijblijven 19:6, 238-243
CrossRef126
Fan Zhang, Ying Yang, Terry Smith, Shu-Wan Kau, Judy M. McConathy, Francisco J. Esteva, Henry M. Kuerer, W. Fraser Symmans, Aman U. Buzdar, Gabriel N. Hortobagyi, Lajos Pusztai. (2003) Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 97:7, 1758-1765
CrossRef127
Susan Lindrud, Michelle Orlick, Nicola Barnard, William N. Hait, Deborah L. Toppmeyer. (2003) Central Nervous System Progression During Systemic Response to Trastuzumab, Humanized Anti-HER-2/neu Antibody, Plus Paclitaxel in a Woman with Refractory Metastatic Breast Cancer. The Breast Journal 9:2, 116-119
CrossRef128
Helen Swede, Kirsten B. Moysich, Janet S. Winston, Thelma C. Hurd, Stephen B. Edge, Maritza Romero-Gutierrez, John S. J. Brooks, Arthur M. Michalek. (2003) Variation of the Prognostic Significance of HER-2 Expression in Breast Cancer According to Tumor Size. The Breast Journal 9:2, 98-105
CrossRef129
TORILL SAUER, GRO WIEDSWANG, GHANIA BOUDJEMA, HANNE CHRISTENSEN, ROLF KARESEN. (2003) Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?. APMIS 111:3, 444-450
CrossRef130
S. M. Ansell, M. J. Ackerman, J. L. Black, L. R. Roberts, A. Tefferi. (2003) Primer on Medical Genomics Part VI: Genomics and Molecular Genetics in Clinical Practice. Mayo Clinic Proceedings 78:3, 307-317
CrossRef131
John R Benson. (2003) The TNM staging system and breast cancer. The Lancet Oncology 4:1, 56-60
CrossRef132
Snezana Susnjar, Zora Neskovic-Konstantinovic, Ljiljana Stamatovic, Suzana Vasovic, Miroslav Strbac, Dragica Nikolic-Vukosavljevic, Dana Jovanovic. (2003) Združeni sadržaj receptora za estrogen i progesteron u predviđanju odgovora na hemioterapiju i hormonsku terapiju u karcinomu dojke. Srpski arhiv za celokupno lekarstvo 131:11-12, 443-448
CrossRef133
Shahla Masood, Marilyn M. Bui. (2002) Prognostic and predictive value ofHER2/neu oncogene in breast cancer. Microscopy Research and Technique 59:2, 102-108
CrossRef134
Regina Gandour-Edwards, Primo N. Lara, Ann K. Folkins, Janine M. LaSalle, Laurel Beckett, Yueju Li, Frederick J. Meyers, Ralph DeVere-White. (2002) DoesHER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?. Cancer 95:5, 1009-1015
CrossRef135
PETER BRYANT-GREENWOOD. (2002) Molecular Diagnostics in Obstetrics and Gynecology. Clinical Obstetrics and Gynecology 45:3, 605-621
CrossRef136
Tanja Fehm, Gerhard Gebauer, Wolfram Jäger. (2002) Clinical Utility of Serial Serum c-erbB-2 Determinations in the Follow-up of Breast Cancer Patients. Breast Cancer Research and Treatment 75:2, 97-106
CrossRef137
Saori Kaneko, Tsilya Gerasimova, William M. Butler, Tommy E. Cupples, Paul L. Guerry, Gwen R. Greene, S.Robert Young. (2002) The Use of FISH on Breast Core Needle Samples for the Presurgical Assessment of HER-2 Oncogene Status. Experimental and Molecular Pathology 73:1, 61-66
CrossRef138
Constantine Dimitrakakis, Manousos Konstadoulakis, Evangelos Messaris, George Kymionis, Maria Karayannis, Dimitrios Panoussopoulos, Stylianos Michalas, George Androulakis. (2002) Molecular markers in breast cancer: Can we use c-erbB-2, p53, bcl-2 and bax gene expression as prognostic factors?. The Breast 11:4, 279-285
CrossRef139
David Gancberg, Tero Järvinen, Angelo di Leo, Ghizlane Rouas, Fatima Cardoso, Marianne Paesmans, Alain Verhest, Martine J. Piccart, Jorma Isola, Denis Larsimont. (2002) Evaluation of HER-2/NEU Protein Expression in Breast Cancer by Immunohistochemistry: An Interlaboratory Study Assessing the Reproducibility of HER-2/NEU Testing. Breast Cancer Research and Treatment 74:2, 113-120
CrossRef140
O Tynninen, J Sjöström, K von Boguslawski, N O Bengtsson, R Heikkilä, P Malmström, B Østenstad, E Wist, V Valvere, E Saksela, T Paavonen, C Blomqvist. (2002) Tumour microvessel density as predictor of chemotherapy response in breast cancer patients. British Journal of Cancer 86:12, 1905-1908
CrossRef141
Jianzhou Wang, Thomas A. Buchholz, Lavinia P. Middleton, D. Craig Allred, Susan L. Tucker, Henry M. Kuerer, Francisco J. Esteva, Gabriel N. Hortobagyi, Aysegul A. Sahin. (2002) Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 94:12, 3107-3114
CrossRef142
Daniel F Hayes, Ann D Thor. (2002) c-erbB-2 in breast cancer: Development of a clinically useful marker. Seminars in Oncology 29:3, 231-245
CrossRef143
S. Tsutsui, S. Ohno, S. Murakami, A. Kataoka, J. Kinoshita, Y. Hachitanda. (2002) EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. European Journal of Surgical Oncology (EJSO) 28:4, 383-387
CrossRef144
Minetta C Liu, Edward P Gelmann. (2002) P53 gene mutations: Case study of a clinical marker for solid tumors. Seminars in Oncology 29:3, 246-257
CrossRef145
Anne Vincent-Salomon, Michel Jouve, Pascal Genin, Paul Fr
CrossRef146
Shinichi Tsutsui, Shinji Ohno, Shigeru Murakami, Yoichi Hachitanda, Shinya Oda. (2002) Prognostic value of c-erbB2 expression in breast cancer. Journal of Surgical Oncology 79:4, 216-223
CrossRef147
Shinichi Tsutsui, Shinji Ohno, Shigeru Murakami, Akemi Kataoka, Junko Kinoshita, Yoichi Hachitanda. (2002) Comparison of the immunohistochemical expression of EGFR, c-erbB2 and p53 protein between primary and recurrent breast cancer. Breast Cancer 9:2, 111-117
CrossRef148
Funda Meric, Mien-Chie Hung, Gabriel N Hortobagyi, Kelly K Hunt. (2002) HER2/neu in the management of invasive breast cancer. Journal of the American College of Surgeons 194:4, 488-501
CrossRef149
P. Eliopoulos, M. Q. Mohammed, K. Henry, S. Retsas. (2002) Overexpression of HER-2 in thick melanoma. Melanoma Research 12:2, 139-145
CrossRef150
Jennifer T. Loud, June A. Peters, Mary Fraser, Jean Jenkins. (2002) Applications of Advances in Molecular Biology and Genomics to Clinical Cancer Care. Cancer Nursing 25:2, 110-122
CrossRef151
Bela Bodey. (2002) The significance of immunohistochemistry in the diagnosis and therapy of neoplasms. Expert Opinion on Biological Therapy 2:4, 371-393
CrossRef152
Takashi Fukutomi, Sadako Akashi-Tanaka. (2002) Prognostic and predictive factors in the adjuvant treatment of breast cancer. Breast Cancer 9:2, 95-99
CrossRef153
Tomohiro Akatsuka, Takuro Wada, Yasuo Kokai, Satoshi Kawaguchi, Kazuo Isu, Katsushige Yamashiro, Toshihiko Yamashita, Norimasa Sawada, Shinya Yamawaki, Seiichi Ishii. (2002) ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94:5, 1397-1404
CrossRef154
Seth Rosenthal, Peter Depowski, Christine Sheehan, Jeffrey Ross. (2002) Applied Immunohistochemistry 10:1, 40-46
CrossRef155
Ichiro Mori, Qifeng Yang, Kennichi Kakudo. (2002) Predictive and prognostic markers for invasive breast cancer. Pathology International 52:3, 186-194
CrossRef156
Hitoshi Tsuda, Hironobu Sasano, Futoshi Akiyama, Masafumi Kurosumi, Tadashi Hasegawa, R. Yoshiyuki Osamura, Goi Sakamoto. (2002) Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma. Pathology International 52:2, 126-134
CrossRef157
Giuseppe Frasci. (2002) Treatment of Breast Cancer with Chemotherapy in Combination with Filgrastim. Drugs 62:Supplement 1, 17-31
CrossRef158
Robert J. Ellis, Carol J. Fabian, Bruce F. Kimler, Ossama Tawfik, Matthew S. Mayo, Carlos Rubin Decelis, William R. Jewell, Carol Connor, Carol Modrell, Mark Praeger, Marilee McGinness, Rita Mehta, John P. Fruehauf. (2002) Factors Associated With Success of the Extreme Drug Resistance Assay in Primary Breast Cancer Specimens. Breast Cancer Research and Treatment 71:2, 95-102
CrossRef159
Attiqa N. Mirza, Nadeem Q. Mirza, Georges Vlastos, S. Eva Singletary. (2002) Prognostic Factors in Node-Negative Breast Cancer. Annals of Surgery 235:1, 10-26
CrossRef160
Ljiljana Stamatovic, Snezana Susnjar, Zora Neskovic-Konstantinovic, Suzana Vasovic, Zorica Tomasevic, Dragica Nikolic-Vukosavljevic. (2002) Predictive value of her-2 in breast cancer: Chemotherapy. Archive of oncology 10:3, 159-161
CrossRef161
Grace McKee, Rosemary Tambouret, Dianne Finkelstein. (2001) Applied Immunohistochemistry 9:4, 352-357
CrossRef162
P. M. Ravdin. (2001) Is Her2 of Value in Identifying Patients Who Particularly Benefit From Anthracyclines During Adjuvant Therapy? A Qualified Yes.. JNCI Monographs 2001:30, 80-84
CrossRef163
Trevor G. Shepherd, Lisa Kockeritz, Michelle R. Szrajber, William J. Muller, John A. Hassell. (2001) The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis. Current Biology 11:22, 1739-1748
CrossRef164
M. Hossein Saboorian, MD, Frank H. Wians, Jr, PhD, Momin T. Siddiqui, MD, Sefik Gokaslan, MD, Linda Hynan, PhD, Sijian Wang, MD, PhD, Barbara B. Haley, MD, Raheela Ashfaq, MD, Eugene P. Frenkel, MD. (2001) Assessment of HER-2/neu Status in Breast Cancer: Automated Cellular Imaging System (ACIS)-Assisted Quantitation of Immunohistochemical Assay Achieves High Accuracy in Comparison With Fluorescence In Situ Hybridization Assay as the Standard. American Journal of Clinical Pathology 116:4, 495-503
CrossRef165
Andrea Ardizzoni, Mara A. Cafferata, Michela Paganuzzi, Rosangela Filiberti, Paola Marroni, Monica Neri, Vincenzo Fontana, Guido Nicol
CrossRef166
Howard Safran, Margaret Steinhoff, Shamlal Mangray, Ritesh Rathore, Thomas Charles King, Li Chai, Katya Berzein, Todd Moore, David Iannitti, Philip Reiss, Terese Pasquariello, Paul Akerman, Daniel Quirk, Robert Mass, Lisa Goldstein, Umadevi Tantravahi. (2001) Overexpression of the HER-2/ neu Oncogene in Pancreatic Adenocarcinoma. American Journal of Clinical Oncology 24:5, 496-499
CrossRef167
Naoto T. Ueno, Dihua Yu, Mien-Chie Hung. (2001) E1A: Tumor suppressor or oncogene? Preclinical and clinical investigations ofE1A gene therapy. Breast Cancer 8:4, 285-293
CrossRef168
Shikha Bose, Mansoor Mohammed, Peter Shintaku, P. Nagesh Rao. (2001) Her-2/neu Gene Amplification in Low to Moderately Expressing Breast Cancers: Possible Role of Chromosome 17/Her-2/neu Polysomy. The Breast Journal 7:5, 337-344
CrossRef169
Syed Abdus Aziz, Shahid Pervez, Shaista Khan, Naila Kayani, Syed Igbal Azam, Mohammed Hussain Rahbar. (2001) Significance of immunohistochemical c-ErbB-2 product localisation pattern for prognosis in human breast cancer. Pathology & Oncology Research 7:3, 190-196
CrossRef170
Elisabeth Mueller-Holzner, Vroni Fink, Thomas Frede, Christian Marth. (2001) Immunohistochemical determination of her2 expression in breast cancer from core biopsy specimens: a reliable predictor of her2 status of the whole tumor. Breast Cancer Research and Treatment 69:1, 13-19
CrossRef171
Gottfried Konecny, Manuel Fritz, Michael Untch, Annette Lebeau, Margrit Felber, Sandra Lude, Malgorzata Beryt, Hermann Hepp, Dennis Slamon, Mark Pegram. (2001) HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer. Breast Cancer Research and Treatment 69:1, 53-63
CrossRef172
Stamatina Kaptain, Lee K. Tan, Beiyun Chen. (2001) Her-2/ neu and Breast Cancer. Diagnostic Molecular Pathology 10:3, 139-152
CrossRef173
Francisco J. Esteva, Gabriel N. Hortobagyi, Aysegul A. Sahin, Terry L. Smith, Dot Mon Chin, Shang -Ying Liang, Lajos Pusztai, Aman U. Buzdar, Sarah S. Bacus. (2001) Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry. Pathology & Oncology Research 7:3, 171-177
CrossRef174
Richard Bell. (2001) Duration of therapy in metastatic breast cancer: management using Herceptin®. Anti-Cancer Drugs 12:7, 561-568
CrossRef175
Hideko Yamauchi, Vered Stearns, Daniel F. Hayes. (2001) The role of c-erbB-2 as a predictive factor in breast cancer. Breast Cancer 8:3, 171-183
CrossRef176
R. Simon, A. Nocito, T. Hubscher, C. Bucher, J. Torhorst, P. Schraml, L. Bubendorf, M. M. Mihatsch, H. Moch, K. Wilber, A. Schotzau, J. Kononen, G. Sauter. (2001) Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer. JNCI Journal of the National Cancer Institute 93:15, 1141-1146
CrossRef177
J.W. Park, D.B. Kirpotin, K. Hong, R. Shalaby, Y. Shao, U.B. Nielsen, J.D. Marks, D. Papahadjopoulos, C.C. Benz. (2001) Tumor targeting using anti-her2 immunoliposomes. Journal of Controlled Release 74:1-3, 95-113
CrossRef178
Gemma Dom
CrossRef179
Hadi Yaziji, MD, Hans-Anton Lehr, MD, PhD, Allen M. Gown, MD, Timothy W. Jacobs, MD, PhD, Stuart J. Schnitt, MD, PhD. (2001) Quantitative Evaluation of HER-2/neu Status in Breast Cancer by Fluorescence In Situ Hybridization and by Immunohistochemistry With Image Analysis. American Journal of Clinical Pathology 115:6, 814-822
CrossRef180
N.J. Bundred. (2001) Prognostic and predictive factors in breast cancer. Cancer Treatment Reviews 27:3, 137-142
CrossRef181
Miriam N. Lango, Dong Moon Shin, Jennifer Rubin Grandis. (2001) Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer. Current Opinion in Oncology 13:3, 168-175
CrossRef182
Susana M. Campos, Richard T. Penson, Aisha R. Mays, Ross S. Berkowitz, Arlan F. Fuller, Annekathryn Goodman, Ursula A. Matulonis, Alona Muzikansky, Michael V. Seiden. (2001) The Clinical Utility of Liposomal Doxorubicin in Recurrent Ovarian Cancer. Gynecologic Oncology 81:2, 206-212
CrossRef183
Amy I. D'Orazio. (2001) Is HER2/neu Overexpression a Predictor of Anthracycline Utility?. Clinical Breast Cancer 2:1, 30-32
CrossRef184
Karen H Antman. (2001) Randomized trials of high dose chemotherapy for breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1471:3, M89-M98
CrossRef185
Pierre Rudolph, Per Alm, Håkan Olsson, Hans-Juergen Heidebrecht, Mårten Fernö, Bo Baldetorp, Reza Parwaresch. (2001) Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. Human Pathology 32:3, 311-319
CrossRef186
A Jukkola. (2001) c-erbB-2 Positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. European Journal of Cancer 37:3, 347-354
CrossRef187
Burkhard H. Brandt, Hartmut Schmidt, Gabriela de Angelis, Kurt S. Zänker. (2001) Predictive laboratory diagnostics in oncology utilizing blood-borne cancer cells – current best practice and unmet needs. Cancer Letters 162, S11-S16
CrossRef188
Junichi Kurebayashi. (2001) Biological and clinical significance of her2 overexpression in Breast Cancer. Breast Cancer 8:1, 45-51
CrossRef189
Yutaka Hatanaka, Kaoru Hashizume, Yuki Kamihara, Hitoshi Itoh, Hitoshi Tsuda, R. Yoshiyuki Osamura, Yoichi Tani. (2001) Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTestTM in breast carcinoma by image analysis. Pathology International 51:1, 33-36
CrossRef190
Hitoshi Tsuda, Yoichi Tani, Tadashi Hasegawa, Takashi Fukutomi. (2001) Concordance in judgments among c-erbB-2 (HER2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma. Pathology International 51:1, 26-32
CrossRef191
G. Lilling, H. Hacohen, J. Nordenberg, T. Livnat, V. Rotter, Y. Sidi. (2000) Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: possible relation to high bcl-2/bax ratio?. Cancer Letters 161:1, 27-34
CrossRef192
G. Zavagno, F. Meggiolaro, A. Pluchinotta, F. Bozza, F. Favretti, R. Marconato, G. Geraci, R. Nistri, P. Fontana, P. Sorrentino, F. Lumachi, A. Toniato, C.R. Rossi, M. Lise. (2000) Influence of age and menopausal status on pathologic and biologic features of breast cancer. The Breast 9:6, 320-328
CrossRef193
Annalisa Volpi, Franca De Paola, Oriana Nanni, Anna Maria Granato, Paola Bajorko, Aldo Becciolini, Emanuela Scarpi, Angela Riccobon, Manuela Balzi, Dino Amadori. (2000) Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. Breast Cancer Research and Treatment 63:3, 181-192
CrossRef194
D. Ziyaie, T.R. Hupp, A.M. Thompson. (2000) p53 and breast cancer. The Breast 9:5, 239-246
CrossRef195
John W. Park, Debasish Tripathy, Michael J. Campbell, Laura J. Esserman. (2000) Biological Therapy of Breast Cancer. BioDrugs 14:4, 221-246
CrossRef196
Gregory J. Tsongalis, Richard W. Cartun, Andrew Ricci. (2000) Gene Amplification as Means for Determining Therapeutic Strategies in Human Cancers. Clinical Chemistry and Laboratory Medicine 38:9, 837-839
CrossRef197
J. Stebbing, E. Copson, S. O’Reilly. (2000) Herceptin (trastuzamab) in advanced breast cancer. Cancer Treatment Reviews 26:4, 287-290
CrossRef198
M.C. Green, J.L. Murray, G.N. Hortobagyi. (2000) Monoclonal antibody therapy for solid tumors. Cancer Treatment Reviews 26:4, 269-286
CrossRef199
Dihua Yu, Mien-Chie Hung. (2000) Role of erbB2 in breast cancer chemosensitivity. BioEssays 22:7, 673-680
CrossRef200
Funda Meric, Nadeem Q. Mirza, Aman U. Buzdar, Kelly K. Hunt, Fred C. Ames, Merrick I. Ross, Raphael E. Pollock, Lisa A. Newman, Barry W. Feig, Eric A. Strom, Thomas A. Buchholz, Marsha D. McNeese, Gabriel N. Hortobagyi, S. Eva Singletary. (2000) Prognostic Implications of Pathological Lymph Node Status After Preoperative Chemotherapy for Operable T3N0M0 Breast Cancer. Annals of Surgical Oncology 7:6, 435-440
CrossRef201
R. Cantero, A.J. Torres, M.L. Maestro, F. Hernando, M.T. Sanz, V. del Barco, A. Gómez, C. Fernández, J.L. Balibrea. (2000) Prognostic value of the quantified expression of p185c-erbb2 in non–small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery 119:6, 1119-1125
CrossRef202
Olufunmilayo I. Olopade, James D. Fackenthal. (2000) BREAST CANCER GENETICS. Hematology/Oncology Clinics of North America 14:3, 705-725
CrossRef203
Tommy Reese, Wilbur R. Harrison, MS, Linda D. Cooley, MD, Russell Vang, MD, Jacki Abrams, MD. (2000) Immunohistochemical Determination of HER-2/neu Expression in Invasive Breast Carcinoma. American Journal of Clinical Pathology 113:5, 669-674
CrossRef204
Angelo Di Leo, MD, PhD, Dina Hertens, MD, Martine Piccart, MD, PhD, David Gancberg, PhD, Marianne Paesmans, MSc, Denis Larsimont, MD, Alain Verhest, MD, PhD, Ghizlane Rouas, Jean-Marie Nogaret, MD, Laurence Lespagnard, PhD. (2000) Sensitivity of HER-2/neu Antibodies in Archival Tissue Samples of Invasive Breast Carcinomas. American Journal of Clinical Pathology 113:5, 675-682
CrossRef205
Raya Mandler, Ekaterina Dadachova, James K Brechbiel, Thomas A Waldmann, Martin W Brechbiel. (2000) Synthesis and evaluation of antiproliferative activity of a geldanamycin–Herceptin™ immunoconjugate. Bioorganic & Medicinal Chemistry Letters 10:10, 1025-1028
CrossRef206
Achim Aigner, Susie S Hsieh, Claudius Malerczyk, Frank Czubayko. (2000) Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol. Toxicology 144:1-3, 221-228
CrossRef207
Todd D. Shuster, Lyubov Girshovich, Timothy M. Whitney, Kevin S. Hughes. (2000) MULTIDISCIPLINARY CARE FOR PATIENTS WITH BREAST CANCER. Surgical Clinics of North America 80:2, 505-533
CrossRef208
Sylvie M
CrossRef209
Allen M. Gown, MD, Timothy W. Jacobs, MD, Melissa J. Barnes, Stuart J. Schnitt, MD, Hadi Yaziji, MD. (2000) HER-2/neu Protein Expression in Breast Cancer Evaluated by Immunohistochemistry. American Journal of Clinical Pathology 113:2, 251-258
CrossRef210
W R Bezwoda. (2000) C-erb-B2 expression and response to treatment in metastatic breast cancer. Medical Oncology 17:1, 22-28
CrossRef211
Roy D. Baynes, Roger D. Dansey, Jared L. Klein, Chatchada Karanes, Lucinda Cassells, Esteban Abella, Wei-Zen Wei, Anne Galy, Wei Du, Gary Wood, William P. Peters. (2000) High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Breast Cancer. Cancer Investigation 18:5, 440-455
CrossRef212
Linda B. Schultz, Barbara L. Weber. (1999) Recent advances in breast cancer biology. Current Opinion in Oncology 11:6, 429
CrossRef213
L. Pusztai, F.J. Esteva, M. Cristofanilli, M-C.Hung† and G.N. Hortobagyi. (1999) Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer. Cancer Treatment Reviews 25:5, 271-277
CrossRef214
Tero A.H. J
CrossRef215
Kirby I. Bland. (1999) The 1999 James Ewing Lecture: In Pursuit of Molecules of Oncogenesis and Neoplastic Therapy. Annals of Surgical Oncology 6:6, 528-541
CrossRef216
David W. Miles, William H. Harris, Cheryl E. Gillett, Paul Smith, Diana M. Barnes. (1999) Effect of c-erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. International Journal of Cancer 84:4, 354-359
CrossRef217
Thelma C. Hurd, Stephen B. Edge, Morton S. Kahlenberg, Paul C. Stomper, Gary M. Proulx, Gary Schwartz, Vijay Khatri, Janet S. Winston. (1999) Treatment of early-stage breast cancer. Current Problems in Cancer 23:4, 149-228
CrossRef218
Fulvia Farabegoli, Claudio Ceccarelli, Donatella Santini, Nicola Baldini, Mario Taffurelli, Domenico Marrano, Davide Trer
CrossRef219
Pierre Rudolph, Gaëtan MacGrogan, Françoise Bonichon, Sven‐Olaf Frahm, Isabelle de Mascarel, Monique Trojani, Michel Durand, Antoine Avril, Jean‐Michel Coindre, Reza Parwaresch. (1999) Prognostic significance of Ki‐67 and topoisomerase IIα expression in infiltrating ductal carcinoma of the breast. Breast Cancer Research and Treatment 55:1, 61-71
CrossRef220
D. A. Cameron, R. C. F. Leonard. (1999) Re: erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer. JNCI Journal of the National Cancer Institute 91:8, 728-728
CrossRef221
Laura M. Vargas-Roig, Francisco E. Gago, Olga Tello, Mar
CrossRef222
P. Viens, J. Jacquemier, V.J. Bardou, F. Bertucci, F. Penault‐Llorca, B. Puig, G. Gravis, S. Oziel‐Taïeb, M. Resbeut, G. Houvenaeghel, J.ens Camerlo, D. Birbaum, J. Hassoun, D. Maraninchi. (1999) Association of angiogenesis and poor prognosis in node‐positive patients receiving anthracycline‐based adjuvant chemotherapy. Breast Cancer Research and Treatment 54:3, 205-212
CrossRef223
Pamela N. Münster, Clifford A. Hudis. (1999) ADJUVANT THERAPY FOR RESECTABLE BREAST CANCER. Hematology/Oncology Clinics of North America 13:2, 391-413
CrossRef224
Silvia Formenti, Garth Green. (1999) AN UPDATE ON RADIATION THERAPY IN BREAST CANCER. Hematology/Oncology Clinics of North America 13:2, 373-389
CrossRef225
Jeffrey S. Ross, Jonathan A. Fletcher. (1999) The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Seminars in Cancer Biology 9:2, 125-138
CrossRef226
Jolanda G. Schrama, Sjoerd Rodenhuis. (1999) Dose-intensive chemotherapy for locally advanced breast cancer. Current Oncology Reports 1:1, 23-30
CrossRef227
Pierre Rudolph, H
CrossRef228
Francisco E. Gago, Olga M. Tello, Angela M. Diblasi, Daniel R. Ciocca. (1998) Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients. The Journal of Steroid Biochemistry and Molecular Biology 67:5-6, 431-437
CrossRef229
Ivan Bièche, Martine Olivi, Marie-Hélène Champème, Dominique Vidaud, Rosette Lidereau, Michel Vidaud. (1998) Novel approach to quantitative polymerase chain reaction using real-time detection: Application to the detection of gene amplification in breast cancer. International Journal of Cancer 78:5, 661-666
CrossRef230
Suzanne Eccles. (1998) c-erbB-2 as a target for immunotherapy. Expert Opinion on Investigational Drugs 7:11, 1879-1896
CrossRef231
Mark D. Pegram, Giovanni Pauletti, Dennis J. Slamon. (1998) Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy. Breast Cancer Research and Treatment 52:1-3, 65-77
CrossRef232
Richard M. Elledge, D. Craig Allred. (1998) Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Research and Treatment 52:1-3, 79-98
CrossRef233
Jeffrey S. Ross, Jonathan A. Fletcher. (1998) The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Stem Cells 16:6, 413-428
CrossRef234
Vered Stearns, Hideko Yamauchi, Daniel F. Hayes. (1998) Circulating tumor markers in breast cancer: Accepted utilities and novel prospects. Breast Cancer Research and Treatment 52:1-3, 239-259
CrossRef235
I. Craig Henderson, Anthony J. Patek. (1998) The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Research and Treatment 52:1-3, 261-288
CrossRef236
Sandrine Cariou, Charles Catzavelos, Joyce M. Slingerland. (1998) Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1. Breast Cancer Research and Treatment 52:1-3, 29-41
CrossRef237
Edison T. Liu. (1998) The uncoupling of race and cancer genetics. Cancer 83:S8, 1765-1769
CrossRef238
C. Kent Osborne. (1998) Steroid hormone receptors in breast cancer management. Breast Cancer Research and Treatment 51:3, 227-238
CrossRef239
Z.U. Rahman, G.N. Hortobagyi, A.U. Buzdar, R. Champlin. (1998) High-dose chemotherapy with autologous stem cell support in patients with breast cancer. Cancer Treatment Reviews 24:4, 249-263
CrossRef240
Daniel Medina, L. Clifton Stephens, Pedro J. Bonilla, C. Annette Hollmann, Denise Schwahn, Charlotte Kuperwasser, D. Joseph Jerry, Janet S. Butel, Raymond E. Meyn. (1998) Radiation-induced tumorigenesis in preneoplastic mouse mammary glands in vivo: Significance ofp53 status and apoptosis. Molecular Carcinogenesis 22:3, 199-207
CrossRef241
Burkhard Brandt, Antje Roetger, Stefan Heidl, Christian Jackisch, Ralf J. Lelle, Gerd Assmann, Kurt S. Zänker. (1998) Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. International Journal of Cancer 76:6, 824-828
CrossRef242
A. Ravaioli, L. Bagli, A. Zucchini, F. Monti. (1998) Prognosis and prediction of response in breast cancer: the current role of the main biological markers.. Cell Proliferation 31:3-4, 113-126
CrossRef243
Duen-Hwa Yan. (1998) Targeting Human Breast Cancer Cells That Overexpress HER-2/neu mRNA by an Antisense Iron Responsive Element. Biochemical and Biophysical Research Communications 246:2, 353-358
CrossRef244
James A. Kaye. (1998) FDA licensure of neumega® to prevent severe chemotherapy‐induced thrombocytopenia. Stem Cells 16:S1, 207-223
CrossRef245
M Colleoni. (1998) Pre-operative chemotherapy and radiotherapy in breast cancer. European Journal of Cancer 34:5, 641-645
CrossRef246
Mariangela Mancini, Monireh Sedghinasab, Katya Knowlton, Amy Tam, David Hockenberg, Benjamin O. Anderson. (1998) Flow cytometric measurement of mitochondrial mass and function: A novel method for assessing chemoresistance. Annals of Surgical Oncology 5:3, 287-295
CrossRef247
Vic Velanovich. (1998) Axillary lymph node dissection for breast cancer: A decision analysis of T1 lesions. Annals of Surgical Oncology 5:2, 131-139
CrossRef248
Lajos Pusztai, Gabriel N. Hortobagyi. (1998) High-dose chemotherapy: how resistant is breast cancer?. Drug Resistance Updates 1:1, 62-72
CrossRef249
Hitoshi Tsuda, Chinami Sakamaki, Shoichiro Tsugane, Takashi Fukutomi, Setsuo Hirohashi. (1998) A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases. Breast Cancer Research and Treatment 48:1, 21-32
CrossRef250
Sylvie Rozan, Anne Vincent-Salomon, Brigitte Zafrani, Pierre Validire, Patricia De Cremoux, Agnès Bernoux, Myriam Nieruchalski, Alain Fourquet, Krishna Clough, Véronique Dieras, Pierre Pouillart, Xavier Sastre-Garau. (1998) No significant predictive value of c- erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. International Journal of Cancer 79:1, 27-33
CrossRef251
E Tzahar. (1998) The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1377:1, M25-M37
CrossRef252
M. Colleoni, A. Coates, O. Pagani, A. Goldhirsch. (1998) Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: Still a question?. Cancer Treatment Reviews 24:1, 15-26
CrossRef253
Jocelyne D. Jacquemier, Frederique M. Penault-Llorca, Francois Bertucci, Zhen Z. Sun, Gilles F. Houvenaeghel, Jeanine A. Geneix, Brigitte D. Puig, Valerie Jeanne H. Bardou, Jacques A. Hassoun, Daniel Birnbaum, Patrice J. Viens. (1998) Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis. The Journal of Pathology 184:2, 130-135
CrossRef254
Giuseppe Albonico, Patrizia Querzoli, Stefano Ferretti, Rosa Rinaldi, Italo Nenci. (1998) Biological Profile of in Situ Breast Cancer Investigated by Immunohistochemical Technique. Cancer Detection <html_ent glyph="@amp;" ascii="&"/> Prevention 22:4, 313-318
CrossRef255
Maria Grazia Sacco, Laura Gribaldo, Ottavia Barbieri, Gino Turchi, Ileana Zucchi, Angelo Collotta, Luca Bagnasco, Domenico Barone, Cristina Montagna, Anna Villa, Erminio Marafante, Paolo Vezzoni. (1998) Establishment and characterization of a new mammary adenocarcinoma cell line derived from MMTV neu transgenic mice. Breast Cancer Research and Treatment 47:2, 171-180
CrossRef256
Anita Yeomans Kinney, Aysegul Sahin, Sally W. Vernon, Ralph F. Frankowski, John F. Annegers, Gabriel N. Hortobagyi, Aman U. Buzdar, Debra K. Frye, Kapil Dhingra. (1997) The prognostic significance of sialyl-tn Antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer 80:12, 2240-2249
CrossRef257
O. Stål, C. Klintenberg, S. Sullivan. (1997) Overexpression of c-erbB-2 protein and locoregional recurrence in node-positive breast cancer. The Breast 6:6, 354-360
CrossRef258
Kathryn S Kolibaba, Brian J Druker. (1997) Protein tyrosine kinases and cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1333:3, F217-F248
CrossRef259
Beverly J Lynch, Donald G Guinee, Joseph A Holden. (1997) Human DNA topoisomerase II-alpha: A new marker of cell proliferation in invasive breast cancer. Human Pathology 28:10, 1180-1188
CrossRef260
John W. Park, Keelung Hong, Dmitri B. Kirpotin, Olivier Meyer, Demetrios Papahadjopoulos, Christopher C. Benz. (1997) Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Letters 118:2, 153-160
CrossRef261
(1997) The uniform approach to breast fine-needle aspiration biopsy. The American Journal of Surgery 174:4, 371-385
CrossRef262
Jeffrey S Ross, Christine Sheehan, Alida M Hayner-Buchan, Robert A Ambros, Bhaskar V.S Kallakury, Ronald Kaufman, Hugh A.G Fisher, Patrick J Muraca. (1997) HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Human Pathology 28:7, 827-833
CrossRef263
(1997) Final Version: The Uniform Approach to Breast Fine-Needle Aspiration Biopsy. The Breast Journal 3:4, 149-168
CrossRef264
Alison Jones. (1997) Primary medical therapy. Cancer Treatment Reviews 23, S33-S40
CrossRef265
ANDREAS MAKRIS. (1997) Application of neoadjuvant chemoendocrine therapy for operable breast carcinomas. European Journal of Cancer Care 6:s1, 16-20
CrossRef266
Jeffrey S. Ross, Christine E. Sheehan, Alida M. Hayner-Buchan, Robert A. Ambros, Bhaskar V.
CrossRef267
Everett E Vokes. (1997) Combined modality therapy of solid tumours. The Lancet 349, S4-S6
CrossRef268
I Craig Henderson, Anthony J Patek. (1997) Are breast cancers in young women qualitatively distinct?. The Lancet 349:9064, 1488-1489
CrossRef269
Joanne L. Blum, Stephen E. Jones, Joseph W. Fay, Neil Senzer, Robert G. Mennel. (1997) Guidelines for systemic therapy of early stage breast cancer. Breast Cancer Research and Treatment 43:3, 259-276
CrossRef270
Christel Moog-Lutz, Catherine Tomasetto, Catherine H. Régnier, Corinne Wendling, Yves Lutz, Danièle Muller, Marie-Pierre Chenard, Paul Basset, Marie-Christine Rio. (1997) MLN64 exhibits homology with the steroidogenic acute regulatory protein (STAR) and is over-expressed in human breast carcinomas. International Journal of Cancer 71:2, 183-191
CrossRef271
W.R. Miller, S.P. Langdon. (1997) Steroid hormones and cancer: (III) Observations from human subjects. European Journal of Surgical Oncology (EJSO) 23:2, 163-177
CrossRef272
Tanja Fehm, Peter Maimonis, Stephen Weitz, Yosh Teramoto, Alexander Katalinic, Wolfram Jäger. (1997) Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Research and Treatment 43:1, 87-95
CrossRef273
Patricia S. Steeg, Jeffrey S. Abrams. (1997) Cancer prognostics: Past, present and p27. Nature Medicine 3:2, 152-154
CrossRef274
(1997) The uniform approach to breast fine-needle aspiration biopsy. Diagnostic Cytopathology 16:4, 295-311
CrossRef275
William E. Grizzle, Russell B. Myers, Upender Marine. (1997) The Use of Biomarker Expression to Characterize Neoplastic Processes. Biotechnic & Histochemistry 72:2, 96-104
CrossRef276
Sue C. Heffelfinger, Elyse E. Lower, Mary Ann Miller, Cecilia M. Fenoglio-Preiser. (1996) Plasma Membrane Phosphotyrosine, Her2-NEU, and Epidermal Growth Factor Receptor in Human Breast Cancer. American Journal of Clinical Oncology 19:6, 552-557
CrossRef277
Guo-Wen Sun, Thomas L. Shook, Gregory L. Kay. (1996) Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. Journal of Clinical Epidemiology 49:8, 907-916
CrossRef278
D.W. Miles, R.D. Rubens. (1996) Management of chemotherapy-resistant breast cancer. The Breast 5:4, 288-292
CrossRef279
Rakesh Kumar, Mahitosh Mandal, Barry J. Ratzkin, Naili Liu, Allan Lipton. (1996) NDF induces expression of a novel 46 kD protein in estrogen receptor positive breast cancer cells. Journal of Cellular Biochemistry 62:1, 102-112
CrossRef280
Christian M. Kurbacher, Ian A. Cree, Ursula Brenne, Howard W. Bruckner, Jutta A. Kurbacher, Peter Mallmann, Peter E. Andreotti, Dieter Krebs. (1996) Heterogeneity ofin vitro chemosensitivity in perioperative breast cancer cells to mitoxantroneversus doxorubicin evaluated by a microplate ATP bioluminescence assay. Breast Cancer Research and Treatment 41:2, 161-170
CrossRef281
S. Robert Young, Wei-Hua Liu, Jo-Ann Brock, S. Terrell Smith. (1996) ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization. Genes, Chromosomes and Cancer 16:2, 130-137
CrossRef282
Wei-Rong Xing, Kennedy W. Gilchrist, Charles P. Harris, Wilner Samson, Lorraine F. Meisner. (1996) FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Research and Treatment 39:2, 203-212
CrossRef283
Shanaz H. Dairkee, Helene S. Smith. (1996) Genetic analysis of breast cancer progression. Journal of Mammary Gland Biology and Neoplasia 1:2, 139-151
CrossRef284
Toncred Marya Styblo, William C. Wood. (1996) ADJUVANT CHEMOTHERAPY IN THE NODE-NEGATIVE BREAST CANCER PATIENT. Surgical Clinics of North America 76:2, 327-341
CrossRef285
Nancy E. Hynes. (1996) ErbB2 activation and signal transduction in normal and malignant mammary cells. Journal of Mammary Gland Biology and Neoplasia 1:2, 199-206
CrossRef286
Josephine Contrino, Gregory Hair, Donald L. Kreutzer, Frederick R. Rickles. (1996) In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nature Medicine 2:2, 209-215
CrossRef287
R. Lupu, M. Cardillo, C. Cho, L. Harris, M. Hijazi, C. Perez, K. Rosenberg, D. Yang, C. Tang. (1996) The significance ofheregulin in breast cancer tumor progression and drug resistance. Breast Cancer Research and Treatment 38:1, 57-66
CrossRef288
J. G. Molland, B. H. Barraclough, V. Gebski, J. Milliken, M. Bilous. (1996) PROGNOSTIC SIGNIFICANCE OF c-erbB-2 ONCOGENE IN AXILLARY NODE-NEGATIVE BREAST CANCER. ANZ Journal of Surgery 66:2, 64-70
CrossRef289
Megha G. Joshi, Arthur K. C. Lee, Massimo Loda, Mauricio G. Camus, Carl Pedersen, Gerald J. Heatley, Kevin S. Hughes. (1996) Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome. Cancer 77:3, 490-498
CrossRef290
Emiel J. TH. Rutgers, Hans L. Peterse. (1996) Future prospects for the staging of breast cancer. Seminars in Surgical Oncology 12:1, 3-11
CrossRef291
G. Albonico, P. Querzoli, S. Ferretti, E. Magri, I. Nenci. (1996) Biophenotypes of Breast Carcinoma in situ Defined by Image Analysis of Biological Parameters. Pathology - Research and Practice 192:2, 117-123
CrossRef292
Johanna Sjoüstroüm, Carl Blomqvist. (1996) Predictive Factors for Response to Cytotoxic Treatment in Advanced Breast Cancer a Review. Acta Oncologica 35:s5, 84-90
CrossRef293
Sami Shousha. (1996) New aspects in the histological diagnosis of breast carcinoma. Seminars in Surgical Oncology 12:1, 12-25
CrossRef294
T. Norberg, T. Jansson, S. Sjoügren, C. Mårtensson, I. Andréasson, M-L. Fjaüllskog, H. Lindman, H. Nordgren, A. Lindgren, L. Holmberg, J. Bergh. (1996) Overview on Human Breast Cancer with Focus on Prognostic and Predictive Factors with Special Attention on the Tumour Suppressor Gene P53. Acta Oncologica 35:s5, 96-102
CrossRef295
Timothy E. Kute, Yasmeen Quadri, Hyman Muss, Nora Zbieranski, Constance Cirrincione, Donald A. Berry, Maurice Barcos, Edison Liu, Ann P. Thor, Frederick Koerner, I. Craig Henderson. (1995) Flow cytometry in node-positive breast cancer: Cancer and leukemia group B protocol 8869. Cytometry 22:4, 297-306
CrossRef296
Patrizia Querzoli, Stefano Ferretti, Giuseppe Albonico, Eros Magri, Daniela Scapoli, Monica Indelli, Ttalo Nenci. (1995) Application of quantitative analysis to biologic profile evaluation in breast cancer. Cancer 76:12, 2510-2517
CrossRef297
Ivan Bièche, Rosette Lidereau. (1995) Genetic alterations in breast cancer. Genes, Chromosomes and Cancer 14:4, 227-251
CrossRef298
Han-Xiang An, Dieter Niederacher, Matthias W. Beckmann, Uwe-Jochen Göhring, Anton Scharl, Frauke Picard, Claudiavan van Roeyen, Hans-Georg Schnürch, Hans G. Bender. (1995) ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues. International Journal of Cancer 64:5, 291-297
CrossRef299
Gary M. Clark. (1995) Prognostic and predictive factors for breast cancer. Breast Cancer 2:2, 79-89
CrossRef300
Howard L. Weiner. (1995) The Role of Growth Factor Receptors in Central Nervous System Development and Neoplasia. Neurosurgery 37:2, 179???194
CrossRef301
Howard L. Weiner. (1995) The Role of Growth Factor Receptors in Central Nervous System Development and Neoplasia. Neurosurgery 37:2, 179-194
CrossRef302
William E. Grizzle, Russell B. Myers, Denise K. Oelschlager. (1995) Prognostic Biomarkers in Breast Cancer: Factors Affecting Immunohistochemical Evaluation. The Breast Journal 1:4, 243-250
CrossRef303
Kapil Dhingra, Walter N. Hittelman, Gabriel N. Hortobagyi. (1995) Genetic changes in breast cancer -consequences for therapy?. Gene 159:1, 59-63
CrossRef304
Peter M. Ravdin, Gary C. Chamness. (1995) The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review. Gene 159:1, 19-27
CrossRef305
Christopher C. Benz, Burkhard H. Brandt, Kurt S. Zänker. (1995) Gene diagnostics provide new insights into breast cancer prognosis and therapy. Gene 159:1, 3-7
CrossRef306
Elizabeth A. Lowenthal, John T. Carpenter. (1995) The use of anthracyclines in the adjuvant treatment of breast cancer. Cancer Treatment Reviews 21:3, 199-214
CrossRef307
Judith E. Karp, Vivian W. Pinn. (1995) Breast Cancer: A Template for Progress Through Multidisciplinary Cancer Research. The Breast Journal 1:3, 128-154
CrossRef308
Enriqueta Felip, Josep Maria Del Campo, Diego Rubio, Maria Teresa Vidal, Ramón Colomer, Begoña Bermejo. (1995) Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer 75:8, 2147-2152
CrossRef309
Daniel W. Visscher, Carlos W. M. Bedrossian. (1995) Editorial comments: C-ERBB-2 in Retrospect: Is it time for molecular cytology?. Diagnostic Cytopathology 12:2, 145-147
CrossRef310
James T. Wu, Mark E. Astill, Shane D. Gagon, Lynn Bryson. (1995) Measurement of c-erbb-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: Correlation with serum tumor markers and membrane-bound oncoprotein. Journal of Clinical Laboratory Analysis 9:3, 151-165
CrossRef311
Christine M. Legler, Charles L. Shapiro, Jay R. Harris, Daniel F. Hayes. (1995) Primary Chemotherapy of Resectable Breast Cancer. The Breast Journal 1:1, 42-51
CrossRef312
Tone I. Andersen, Elisabeth Paus, Jahn M. Nesland, Sara J. McKenzie, Anne-Lise Bø rresen. (1995) Detection of C-ERBB-2 Related Protein in Sera from Breast Cancer Patients Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. Acta Oncologica 34:4, 499-504
CrossRef313
(1995) Abstracts. Cancer Investigation 13:s1, 1-61
CrossRef314
Robert Millikan, Lynn Dressler, Joseph Geradts, Mark Graham. (1995) The need for epidemiologic studies of in-situ carcinoma of the breast. Breast Cancer Research and Treatment 35:1, 65-77
CrossRef315
H. Shelton Earp, Thomas L. Dawson, Xiong Li, Hong Yu. (1995) Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Research and Treatment 35:1, 115-132
CrossRef316
William G. Cance, Edison T. Liu. (1995) Protein kinases in human breast cancer. Breast Cancer Research and Treatment 35:1, 105-114
CrossRef317
Kazuyoshi Motomura, Hiroki Koyama, Shinzaburo Noguchi, Hideo Inaji, Chihiro Azuma. (1995) Detection of c-erbB-2 gene amplification in nipple discharge by means of polymerase chain reaction. Breast Cancer Research and Treatment 33:1, 89-92
CrossRef318
Emil Frei. (1994) Randomized clinical trials and other approaches in clinical research. Cancer 74:S9, 2610-2613
CrossRef319
(1994) Adjuvant Therapy for Breast Cancer. New England Journal of Medicine 331:11, 741-746
Full Text320
Goldhirsch, Aron, , Gelber, Richard D., . (1994) Understanding Adjuvant Chemotherapy for Breast Cancer. New England Journal of Medicine 330:18, 1308-1309
Full Text321
Craig I. Henderson. (1994) Adjuvant systemic therapy for early breast cancer. Cancer 74:S1, 401-409
CrossRef
- Letters
